



1994-1995 Resident, Division of General Surgery.  
UMDNJ  
New Brunswick, NJ

1995-1998 Resident, Division of Urology.  
UMDNJ  
New Brunswick, NJ

1998-1999 Chief Resident, Division of Urology.  
UMDNJ  
New Brunswick, NJ

1999-2002 Fellowship in Urologic Oncology.  
Department of Urology  
UCLA School of Medicine  
Los Angeles, CA

2001-2002 Fellowship  
K30 Graduate Training Program in  
Translational Investigation  
UCLA School of Medicine  
Los Angeles, CA

#### **CERTIFICATIONS**

Diplomate, National Board of Medical Examiners, 1994.

The New Jersey Kidney Stone Treatment Center Extracorporeal Shock Wave Lithotripsy Training Program, 1999.

California fluoroscopy supervisor and operator, 2000-2002.

Investigator responsibilities toward Investigational Review Board (IRB) and regulatory concerns with an emphasis on conducting clinical research in gene based medicine, 2000-2002.

University of California Los Angeles, Certificate of Completion, Training in Protecting Human Research Subjects, 2000-2002.

University of California Los Angeles, Certificate of Completion, Good Manufacturing Practice and Good Laboratory Practice, 2001-2003.

University of California HIPAA Training, 2003.

Society of Urologic Oncology Fellowship Certification, 2002.

Diplomat, American Board of Urology, 2004.

Fellow, American College of Surgeons, 2005.

#### **ACADEMIC APPOINTMENTS**

2006 Associate Professor, Step 1, UCLA Department of Urology  
2004 Assistant Professor, Step 4, UCLA Department of Urology  
2002 Assistant Professor, Step 3, UCLA Department of Urology  
2001 Visiting Assistant Professor, UCLA Department of Urology  
1999 Clinical Instructor, UCLA Department of Urology

#### **PROFESSIONAL ACTIVITIES:**

2007- Kidney Cancer Prognostic Factor Committee, Societe Internatinale d'Urology

2006- Program Abstract Review Committee, American Urological Association

2005- American Urological Association Complementary and Alternative Medicine Committee

2003-Southwest Oncology Group (SWOG) Genitourinary Committee

2003-American College of Surgeons Oncology Group GU Committee

#### **HOSPITAL COMMITTEES:**

2005- Scientific Review Committee for Human Embryonic Stem Cell Research

2004- UCLA Institutional Review Board

2003-Jonsson Comprehensive Cancer Center (JCCC) Internal Scientific Peer Review Committee (ISPRC): *Acting Chair in Chair's absence.*

2003- Jonsson Comprehensive Cancer Center (JCCC) Data and Safety Monitoring Board (DSMB): *Acting Chair in Chair's absence.*

2000-Clinical Trials Working Group, UCLA Department of Urology.

1995-1998 OPTIMAP Critical Care Pathway Committee for TURP, TURBT,

Radical prostatectomy, Radical cystectomy with ileal conduit and continent urinary diversion, Robert Wood Johnson University Hospital.

**PROFESSIONAL SOCIETIES & MEMBERSHIPS:**

American Association for Cancer Research  
Fellow, American College of Surgeons  
American Society of Clinical Oncology  
American Urological Association  
International Churchill Society  
Western Section American Urological Association  
Member, Southwest Oncology Group (SWOG)  
Member, Jonsson Comprehensive Cancer Center  
Member, UCLA Center for Integrative Medicine  
International Society for Biological Therapy of Cancer  
Member, Society of Urologic Oncology

**EDITOR:**

Advances in the Management of Renal Cell Carcinoma. Proceedings of the Irish Society of Surgical Oncology. Excerpta Medical International. The Netherlands, 2003.

**REVIEWER:**

The Journal of Urology  
Urology  
British Journal of Urology International  
The Journal of Cancer Integrative Medicine  
European Urology  
Urologic Oncology  
Clinical Cancer Research  
BCW Clinical Pathology  
Nutrition and Cancer  
Canadian Institutes of Health Research

**EDITORIAL BOARDS**

The Journal of Cancer Integrative Medicine  
The Bladder Journal  
American College of Physicians Information and Education Resource  
European Urology

## **CONSULTANCY**

Galil Medical Ltd., Yokneam, Israel

Vical Corporation, San Diego, CA

Chiron Corporation, Emoryville, CA

Wilex Corporation, Germany

Gerson Lehrman Group Council Member

## **HONORS/AWARDS**

- 2004 Second place, Miley B. Wesson Essay Contest, Western Section American Urological Association, San Diego, CA, senior author.
- 2003 Second place, AUA/ACMI clinical essay contest. American Urological Association Annual Meeting, Chicago, fourth author.
- 2003 Third place, AUA/ACMI clinical essay contest. American Urological Association Annual Meeting, Chicago, third author.
- 2002 Second Prize, Joseph F. McCarthy essay contest, Western Section American Urological Association, 2<sup>nd</sup> author.
- 2002 First Prize Winner, Miley Wesson/Proctor and Gamble Resident Essay contest, Western Section American Urological Association, 4<sup>th</sup> author.
- 2002 American Society of Clinical Oncology Merit Award, 1<sup>st</sup> author.
- 2002 American Society of Clinical Oncology Merit Award, 2<sup>nd</sup> author.
- 2001 American Society of Clinical Oncology Merit Award, 2<sup>nd</sup> author.
- 1999 Pfizer Scholars in Urology Award.
- 1998 Third Prize, Basic Science Category, The Philadelphia Urological Society Residents Competition.
- 1997 Pfizer Scholars in Urology Award.

- 1993 Gallo Award, Clinical Oncology, Cancer Institute of New Jersey, Scientific Retreat.
- 1991 Second prize, Clinical Research, American Urological Association Prize Essay Contest.

**GRANTS and RESEARCH SUPPORT**

- 2002-2006 NIH K23 Research Career Development Award: Genetic and Molecular Characterization of kidney cancer. \$540,000 (PI: Pantuck)
- 2002-2007 NIH RFA: Chemoprevention of Superficial Bladder Cancer. \$7,466,331 (PI: Belldgrun)
- 2004-2008 US Army/DoD IDEA Grant. A Novel Assay of Citrate, Choline, and Spermine in Prostate Cancer \$375,000 (PI Thomas)
- 2005-2007 Randomized, double blind, placebo controlled phase III study of pomegranate juice (*Pom Wonderful*) for men with rising PSA following surgery or radiation. \$490,750 (PI Pantuck)
- 2004-2005: Pom-Wonderful: Estrogenic activity of pomegranate seeds \$15,525. (PI: Pantuck)
- 2004-2006: Phase I: Phase I study of adenovirus GM-CSF-CA IX modified autologous dendritic cells for metastatic kidney cancer. \$250,000. (Co-PI: Pantuck)
- 2003-2004 Amgen Corporation: Protein Biomarker evaluation of Renal Cell Carcinoma. \$109,000. (PI: Pantuck)
- 2002-2003 Xcyte: A Phase I Safety Study of Xcellerate in Patients with Hormone Refractory Prostate Cancer. \$113,533 (PI: Pantuck)
- 2002-2204 Transgene: Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010 (MVA-MUC1-Il2) in Patients with Adenocarcinoma of the Prostate (TG4010.03). \$101,299. (PI: Pantuck)
- 2002-2004: Pom-Wonderful: Pomegranate juice to stop or slow the progression of prostate cancer in men with rising PSA after failed primary therapy. \$347,000. (PI: Pantuck)
- 2002-2004: Chiron Corp. Pilot study of ability of IL-2 to clear circulating tumor cells in patients with metastatic renal cell carcinoma. \$57,000 (PI: Pantuck).
- 2002-2005 Department of Defense. Molecular Characterization of Androgen Independence to Delay Progression to Hormone Refractory Prostate Cancer. \$572,000. (PI: Belldgrun).

2001-2003 Ortho-Biotech Perioperative recombinant human erythropoietin for select patients undergoing radical nephrectomy followed by an FDA approved schedule of Interleukin-2 Immunotherapy. Protocol PR00-28-042. \$185,000. (PI: Pantuck)

2001-2002: EMD Pharmaceuticals. High Throughput analysis using tissue microarrays to determine the expression of KS antigen in normal kidney, primary renal cell carcinoma, and metastatic renal cell carcinoma. \$137,000 (PI:Pantuck)

2001-2003 MD Anderson Cancer Center/Charles Dana Foundation. The effect of psychosocial factors on survival in patients with metastatic renal cell carcinoma. \$30,000. (UCLA PI: Pantuck).

2001-2002 Robert Winston Seed Money for Complementary Medicine Research. \$100,000 (Co-PI: Pantuck).

1999-2002 NIH K12 National Research Service Award Cancer Gene Medicine Training Program. Total funding \$175,000. (PI: Economou).

1990 American Foundation for Urologic Disease Summer Student Research Fellowship.

**INVITED LECTURES:**

1. Management of esoteric penile injuries. Department of Urology, New Jersey Medical School. Newark, NJ. August 8, 1997.
2. Evaluation of hematuria. UCLA School of Medicine. July 30, 1999.
3. Nutrition and prostate cancer. UCLA Prostate Cancer Education Group. September 9, 1999.
4. Current controversies in the surgical management of renal cell carcinoma. Chiron/UCLA Kidney Cancer Program Preceptorship. Los Angeles, CA. September 12, 1999.

5. Immune and Gene Therapy for Renal Cell Carcinoma. Plenary lecture, Basic Oncology. Okinawa Urologic Research Forum. Okinawa, Japan. January 29, 2000.
6. Gene therapy for kidney cancer. Chiron/UCLA Kidney Cancer. Program Preceptorship. Los Angeles, CA. March 12, 1999.
7. Hormone refractory prostate cancer. UCLA Prostate Cancer Education Group. April 13, 2000.
8. Bladder cancer 2000: new directions. Marian Medical Center Cancer Forum. Santa Maria, CA. November 10, 2000.
9. Hormone therapy for prostate cancer: when to start? UCLA Prostate Cancer Education Group. January 8, 2001.
10. The role of nephrectomy in renal cancer biology. Immunotherapy of Renal Cancer Workshop. Hospital Universitario Virgen de las Nieves. Granada, Spain. February 17, 2001.
11. Management of advanced renal cell carcinoma. Mayo Clinic. Rochester, MN. February 19, 2001.
12. The role of nephrectomy in metastatic renal cell carcinoma. Baylor University, Houston, TX. March 14, 2001.
13. Optimizing prostate cancer gene therapy using Herpes Simplex Virus 1 Thymidine Kinase Gene Mutants. Sixth Annual Gene Medicine Symposium, UCLA School of Medicine. May 21, 2001.
14. The role of nephrectomy in advanced renal cell carcinoma. Jefferson Medical School. Philadelphia, PA. January 24, 2002.
15. Complementary Medicine and Prostate Cancer. Midway Hospital. Los Angeles, CA. September 16, 2002.
16. The role of nephrectomy and immunotherapy in metastatic renal cell carcinoma. Tampa VA Hospital, Tampa, FL. September 18, 2002.
17. Complementary medicine in prostate cancer. Harbor Hospital. Torrance, CA. October 3, 2002.
18. Complementary medicine in urology. Valley Presbyterian Hospital. Los Angeles, CA. October 8, 2002.
19. Molecular in vivo imaging of prostate cancer using green fluorescence protein. 9<sup>th</sup> Prouts Neck Meeting on Prostate Cancer. Prouts Neck, Maine. November 10, 2002.

20. Phase III study of Iressa and green tea polyphenol extracts in the chemoprevention of smoking related, superficial bladder cancer. Society of Urologic Oncology, Bethesda, MD. December 7, 2002.
21. Prognostication and Clinical Outcome Algorithms for Renal Cell Carcinoma. Irish Society of Surgical Oncology. Dublin, Ireland. January 24, 2003.
22. The Role of Nephrectomy and Immunotherapy in a Combined Approach to Metastatic Kidney Cancer. Irish Society of Surgical Oncology. Dublin, Ireland. January 24, 2003.
23. Prostate Nerve block for transrectal ultrasound guided prostate needle biopsy. UCLA State of the Art, February 9, 2003.
24. Clinical outcome algorithms and the role of nephrectomy and immunotherapy in metastatic kidney cancer. Baylor University Medical Center. Dallas, TX. March 21, 2003.
25. Recent developments in the treatment of kidney cancer. Chiron Sales Education Network. May 21, 2003.
26. Changing Concepts in the Management of Metastatic RCC. Howard University. Washington, DC. October 28, 2003.
27. The UCLA Integrated Staging System. Conference on the Multidisciplinary approach to the Treatment of Metastatic Renal Cell Carcinoma. Sintra, Portugal. November 25, 2003.
28. Nephrectomy and Interleukin-2 for Metastatic RCC. Conference on the Multidisciplinary approach to the Treatment of Metastatic Renal Cell Carcinoma. Sintra, Portugal. November 25, 2003.
29. Moderator: Prostate Cancer Epidemiology and Natural History. American Urological Association, San Francisco, CA, 2004.
30. Prostate Cancer Prevention 2004: Marian Medical Center. Marian, CA, 2004.
31. Nonsurgical techniques for managing small renal lesions. First International Congress on Bladder and Kidney Cancer. Orlando, FL. August 13, 2004.
32. Interferon vs. IL-2 following nephrectomy for metastatic renal cell carcinoma. First International Congress on Bladder and Kidney Cancer. Orlando, FL. August 14, 2004.
33. Update on the Treatment of RCC. Shin-Kong Wu-Su Memorial Hospital, Taipei, Taiwan, August 27, 2004.

34. The Role of Combined Nephrectomy and Immunotherapy for Metastatic RCC. Special Lecture, Taiwan Urological Association, Taipei, Taiwan, August 28, 2004.
35. Update on RCC Staging Algorithms and New Surgical Approaches to the Management of Small Renal Masses. National Taiwan University, Taipei, Taiwan, August 30, 2004.
36. Prostate Cancer and Pomegranate Juice: Preclinical and Clinical Data, Future Directions. Prostate Cancer Foundation 11<sup>th</sup> Annual Scientific Retreat. Lake Tahoe, Nevada, October 24, 2004.
37. Immunohistochemical analysis of the mTOR pathway in Renal Cell Carcinoma. Wyeth, Cambridge, MA, January 17, 2005.
38. Prostate Cancer and Pomegranate Juice: Preclinical and Clinical Data, Phase III Study. Prostate Cancer Foundation Investigator's Meeting. Santa Monica, CA. February 4, 2005.
39. Transrectal Ultrasound of the Prostate: Strategies for Repeat Biopsy. UCLA State of the Art Urology. Marina del Ray, CA. March 13, 2005.
40. Interferon vs. Interleukin-2 Following Nephrectomy for Metastatic Renal Cell Carcinoma. Current Treatment Approaches for Renal Cell Carcinoma. Portland, OR, March 16, 2005.
41. Molecular profiling, tissue microarray, and proteomic analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. Tumor Vaccine and Cellular Therapy Working Group. Anaheim, CA. April 15, 2005.
42. Nutritional Interventions for prostate cancer prevention and treatment. Jonsson Comprehensive Cancer Center Intramural Research Series. May 10, 2005.
43. Chemoprevention of Bladder Cancer 2005. Second International Congress on Bladder and Kidney Cancer. Orlando, FL. July 17, 2005.
44. Laparoscopic and Ablative Techniques for Small Renal Masses. Hong Kong Urological Society. Hong Kong, China, August 30, 2005.
45. Patient Selection and Predicting Response to IL-2 in Patients with Metastatic Renal Cell Carcinoma. Samsung

Medical Center, Seoul, Korea. September 1, 2005.

46. Patient Selection and Predicting Response to IL-2 in Patients with Metastatic Renal Cell Carcinoma. Korean Urological Oncology Society, Seoul, Korea. September 2, 2005.
47. Nutritional Interventions for prostate cancer prevention and treatment. Ted Mann Family Resource Center Insights Into Cancer Series. September 13, 2005.
48. Pomegranates, Polyphenols, and Prostate Cancer. Grand Rounds, Harbor-UCLA Medical Center. January 5, 2005.
49. Minimally Invasive Treatment Options for Renal Cell Carcinoma. 5<sup>th</sup> Multi-Disciplinary Symposium on Genitourinary Cancers. January 27, 2005.
50. Cytoreductive nephrectomy: is it still imperative in the era of targeted therapy? Innovations and Challenges in Renal Cancer. Second Cambridge Conference. Cambridge, MA, April 28, 2006.
51. Non-surgical approaches to localized RCC: standard of care? Third International congress on Kidney and Bladder Cancer. Orlando, FL, August 4, 2006.

#### **PRESENTATIONS:**

1. Pantuck AJ, Baniel J, Kirkali Z, Zomorodian N, Yoosepowich O, Belldegrun AS: A novel resectoscope for transurethral resection of bladder tumors and the prostate. World Congress of Endourology, Cleveland, Ohio, August 17, 2006.
2. Seeram NP, Pantuck AJ, Belldegrun A, Heber D. Phase II study of pomegranate juice in prostate cancer patients and its pharmacokinetics and metabolism in health volunteers. 47<sup>th</sup> Annual meeting of the American Society of Pharmacognosy, Arlington, Virginia, USA. Aug 5-9, 2006.
3. Figlin R, Seligson D, Wu H, Thomas G, Leppert J, O'Toole T, Dukart G, Gibbons J, Belldegrun A, Pantuck AJ: Characterization of the mTOR Pathway in Renal Cell Carcinoma and its Use in Predicting Patient Selection for Agents Targeting this Pathway. American Society of Clinical Oncology, Orlando, FL. May, 2005.
4. Pantuck AJ, Fang X, Liu X, Seligson D, Horvath S, Leppert J, Belldegrun A, Figlin R: Gene Expression and Tissue Microarray Analysis of Interleukin-2 Complete Responders in Patients with Metastatic Renal Cell Carcinoma. American Society of

Clinical Oncology, Orlando, FL. May, 2005.

5. Dreicer R, Ahman R, Pantuck A, Beunkens C, Bizouarn N, Acres B, Maciejewska C, Squiban P: MVA-MUC1-IL2 VACCINE IMMUNOTHERAPY FOR PATIENTS POST-PROSTATECTOMEY WITH RISING PSA AND NO EVIDENT METASTASES. American Society of Clinical Oncology, Orlando, FL. May, 2005.
6. Lam J, Leppert J, Yu H, Seligson D, Dong J, Horvath S, Pantuck AJ, Figlin R, Belldegrun AS: Expression of the Vascular Endothelial Growth Factor Family in Tumor Dissemination and Disease Free Survival in Clear Cell Renal Cell Carcinoma. American Society of Clinical Oncology, Orlando, FL. May, 2005.
7. Lam J, Leppert J, Yu H, Seligson D, Dong J, Horvath S, Pantuck AJ, Figlin R, Belldegrun AS: Targeting the Vascular Endothelial Growth Factor Pathway in Renal Cell Carcinoma, a Tissue Array Based Analysis. American Society of Clinical Oncology, Orlando, FL. May, 2005.
8. Pantuck AJ, Fang X, Liu X, Seligson D, Horvath S, Leppert J, Belldegrun A, Figlin R: Complete Reponse to Immunotherapy in Metastatic Renal Cell Carcinoma: Gene Expression and Tissue Microarray Analysis. American Urological Association, San Antonio, TX. May, 2005.
9. Pantuck AJ, Leppert J, Zomorodian N, Seeram N, Seiler D, Liker H, Wang H, Elashoff R, Heber D, Belldegrun A. Phase II Study of Pomegranate Juice for Men with Rising PSA following Surgery or Radiation for Prostate Cancer. American Urological Association, San Antonio, TX. May, 2005.
10. Pantuck AJ, Seligson D, Wu H, Thomas G, Leppert J, O'Toole T, Dukart G, Gibbons J, Belldegrun A, Figlin R: Characterization of the mTOR Pathway in RCC and its Use in Predicting Patient Selection for Agents Targeting this Pathway. American Urological Association, San Antonio, TX. May, 2005.
11. Jones J, Spentzos D, Out H, Aivado M, Kolia S, Paullus S, Belldegrun AS, Figlin R, Libermann T, Pantuck AJ: Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer. American Urological Association, San Antonio, TX. May, 2005.
12. Lam J, Patard JJ, Leppert J, Guille F, Lobel B, Abbou C, Chopin D, Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R, Li N, Pantuck AJ, Li G, Figlin RA, Belldegrun A: Prognostic Significance Of T3a Renal Cell Carcinoma With Adrenal Gland Involvement: An International Multicenter Experience. American Urological Association, San Antonio, TX. May, 2005.

13. Leppert J, Lam J, Yu H, Seligson D, Dong J, Horvath S, Pantuck A, Figlin R, Belldegrun A: Endothelial Expression of Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3), but not VEGFR-1 or VEGFR-2, Predicts Survival in Clear Cell Renal Cell Carcinoma (RCC). American Urological Association, San Antonio, TX. May, 2005.
14. Leppert J, Lam J, Yu H, Seligson D, Dong J, Horvath S, Pantuck A, Figlin R, Belldegrun A: Hematogenous Versus Lymphatic Dissemination: The role of the Vascular Endothelial Growth Factor (VEGF) Family in the Metastatic Process of Clear Cell Renal Cell Carcinoma. American Urological Association, San Antonio, TX. May, 2005.
15. Leppert J, Lam J, Yu H, Seligson D, Dong J, Horvath S, Pantuck A, Figlin R, Belldegrun A: Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is Highly Expressed in the Tumor Endothelium of Clear Cell but not Papillary Renal Cell Carcinoma (RCC): Implications for Therapy. American Urological Association, San Antonio, TX. May, 2005.
16. Leppert J, Lam J, Yu H, Seligson D, Dong J, Horvath S, Pantuck A, Figlin R, Belldegrun A: Molecular Tumor Grading of Clear Cell Renal Cell Carcinoma Using Protein Expression of the Vascular Endothelial Growth Factor (VEGF) Family. American Urological Association, San Antonio, TX. May, 2005.
17. Leppert J, Lam J, Yu H, Seligson D, Dong J, Horvath S, Pantuck A, Figlin R, Belldegrun A: Expression of Vascular Endothelial Growth Factor A (VEGF-A), VEGF Receptor 1 (VEGFR-1) and VEGFR-2 in Clear Cell and Papillary Renal Cell Carcinoma (RCC): Implications for Therapy. American Urological Association, San Antonio, TX. May, 2005.
18. Leppert J, Lam J, Yu H, Seligson D, Dong J, Horvath S, Pantuck A, Figlin R, Belldegrun A: Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is Preferentially Expressed in Papillary Renal Cell Carcinoma (RCC). American Urological Association, San Antonio, TX. May, 2005.

19. Jones J, Spentzos D, Out H, Aivado M, Kolia S, Paullus S, Belldegrun AS, Figlin R, Pantuck AJ, Libermann T: Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer. American Association for Cancer Research. Anaheim, CA. April, 2005.
20. Jean-Jacques Patard, Nathalie Rioux-Leclercq, Luca Cindolo, Vincenzo Ficarra, Ken-ryu Han, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, François Guillé, Dominique K Chopin, Peter FA Mulders, Christopher G Wood, David A Swanson, Robert A Figlin, Arie S Belldegrun and Allan J Pantuck. The prognostic value of histologic subtypes in Renal Cell Carcinoma. A multicenter experience in 4063 patients. XXth Congress of the European Association of Urology. Istanbul, Turkey, March, 2005.
21. Seiler D, Leppert J, Lam J, Li N, Li G, Pantuck A, Figlin R, Belldegrun A: Microvascular invasion is associated with tumor metastasis and survival in patients with clear cell renal cell carcinoma. European Association of Urology, Vienna, March 25, 2005.
22. Pantuck AJ, Figlin RA, Horvath S, Fang Z, Seligson D, Belldegrun A: Characterization of Complete Responders to IL-2 Using Gene Expression Analysis and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma. International Society for Biologic Therapy. San Francisco, November, 2004.
23. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ: P53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized renal cell carcinoma: implications for surveillance and adjuvant clinical trials. Western Section American Urological Association. San Diego, CA, 2004.
24. Pantuck AJ, Belldegrun AS: Interim Results: Phase II study of pomegranate juice in men with recurrent prostate cancer. POM Wonderful Research Summit. Marina del Rey, CA, 2004.
25. Dreicer R, Ahman R, Pantuck A, Beunkens C, Bizouarn N, Acres B, Maciejewska C, Squiban P: MVA-MUC1-IL2 VACCINE IMMUNOTHERAPY FOR PATIENTS POST-PROSTATECTOMEY WITH RISING PSA AND NO EVIDENT METASTASES. American Society of Gene Therapy, Minneapolis, MN, 2004.

26. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ: P53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized Renal Cell Carcinoma: Implications for surveillance and adjuvant clinical trials. American Society for Clinical Oncology. New Orleans, LA, 2004.
27. Shvarts O, Said J, Lam J, Pantuck AJ, Seligson D, Aldridge M, Bui M, Liu X, Horvath S, Belldegrun A: Clinical, Pathological, and Molecular Correlations of Necrosis in the Primary Tumor of Patients with Renal Cell Carcinoma. American Society for Clinical Oncology. New Orleans, LA, 2004.
28. Glode M, Pantuck AJ, Higano C, Meyer J, Hani J, Craig S, Berenson R, Frohlich M: A phase I/II Study of Xcellerated T cells in men with hormone refractory prostate cancer. American Society for Clinical Oncology. New Orleans, LA, 2004.
29. Patard JJ, Kim H, Dorey F, Pantuck AJ, Ficarra V, Cindolo L, Zisman A, De La Taille A, Tostain J, Artibani W, Wood C, Abbou C, Lobel B, Mulders P, Chopin D, Guillé F, Swanson D, Figlin R, and Belldegrun A: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. American Urological Association, San Francisco, CA, 2004.
30. Lam J, Shvarts O, Rao P, Liu X, Li G, Figlin R, Belldegrun A, Pantuck AJ: PROGNOSTIC IMPACT OF CYTOGENETIC FINDINGS IN RENAL CELL CARCINOMA FOLLOWING SURGICAL RESECTION. American Urological Association, San Francisco, CA, 2004.
31. Patard JJ, Kim H, Dorey F, Ficarra V, Cindolo L, Zisman A, De La Taille A, Tostain J, Artibani W, Wood C, Abbou C, Lobel B, Mulders P, Chopin D, Guillé F, Swanson D, Figlin R, and Belldegrun A, Pantuck AJ: The prognostic value of histologic subtypes in Renal Cell Carcinoma (RCC). A multicenter experience in 4063 patients. American Urological Association, San Francisco, CA, 2004.
32. Patard JJ, Kim H, Dorey F, Pantuck AJ, Ficarra V, Cindolo L, Zisman A, De La Taille A, Tostain J, Artibani W, Wood C, Abbou C, Lobel B, Mulders P, Chopin D, Guillé F, Swanson D, Figlin R, and Belldegrun A: The use of UISS (UCLA Integrated Staging System) to predict survival in renal cell carcinoma: An international multicenter study in 4202 patients. American Urological Association, San Francisco, CA, 2004.

33. Lam J, Shvarts O, Alemozaffarder M, Kim H, Wang H, Pantuck AJ, Smith R, Belldegrun A: Nephron sparing surgery as the new gold standard for T1 < 7 cm. renal cell carcinoma: results of a contemporary UCLA series. American Urological Association, San Francisco, CA, 2004.
34. Pantuck AJ, Seligson D, Huang Y, Horvath S, Bui M, Zisman A, Han K, Janzen N, Figlin R, Belldegrun A: KSA (EPCAM) EXPRESSION IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN RENAL CELL CARCINOMA. American Society of Clinical Oncology, Chicago, IL, 2003.
35. Rao J, Lu QY, Pantuck AJ, Jin Y, Zhang Z, Belldegrun A, Heber D: Green tea and its catechins stimulate actin polymerization and inhibit cell growth and motility on an in vivo bladder cancer carcinogenesis model. American Association of Cancer Research, Toronto, Canada, 2003.
36. Han KR, Bui MHT, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukoyama H, Figlin RA, and Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. American Urological Association, Chicago, IL, 2003.
37. Bui M, Seligson D, Han K, Pantuck AJ, Dorey F, Huang Y, Horvath S, Leibovich B, Chopra S, Liao S, Standbridge E, Lerman M, Palotie A, Figlin R, Belldegrun A: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma. American Urological Association, Chicago, IL, 2003.
38. Han K, Pantuck A, Freitas D, Cuevas C, Kim H, Lugg J, Childs S, Cohen J, Miller R, Shuman B, Jason M, Shore N, Moore Y, Zisman A, Krupski T, Lee J, Zincke H, Belldegrun A: Salvage Cryosurgery Using 3<sup>rd</sup> Generation Cryo "Needles" American Urological Association, Chicago, IL, 2003.
39. Han K, Bluemer I, Pantuck A, Zisman A, Janzen N, Kim H, Mulder P, Dorey F, Dinney C, Wood C, Swanson D, Figlin R, Belldegrun A: International Prognostication of Renal Cell Carcinoma: American Urological Association, Chicago, IL, 2003.
40. Palapattu GS, Pantuck A, Dorey F, Belldegrun A: Collecting System Invasion is a Poor Prognostic Factor in Renal Cell Carcinoma (RCC): Impact on Prognosis and Future Staging Classification. American Urological Association, Chicago, IL, 2003.

41. Zisman A, Pantuck A, Bui M, Said J, Caliliw R, Rao N, Shintaku P, Berger F, Gambhir S, and Belldegrun A: A Metastatic Tumor model for non-hereditary type 2 chromophil (Papillary) renal cell carcinoma expressing CA IX. American Urological Association, Chicago, IL, 2003.
42. Pantuck AJ, Seligson D, Huang Y, Horvath S, Bui M, Zisman A, Han K, Janzen N, Figlin R, Belldegrun A: KSA (EPCAM) EXPRESSION IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN RENAL CELL CARCINOMA. American Urological Association, Chicago, IL, 2003.
43. Singer J, Pantuck AJ, Zisman A, Figlin R, Belldegrun A, Gritsch HA: Long-term outcomes of renal cell carcinoma after kidney transplantation: the UCLA experience. American Urological Association, Chicago, IL, 2003.
44. Leibovich BC, Pantuck AJ, Dorey F, Han K, Figlin R, Belldegrun A: Scoring algorithm to predict survival after nephrectomy and immunotherapy (SANI Score) for metastatic RCC: a stratification tool for perspective clinical trials. American Urological Association, Chicago, IL, 2003.
45. Moukoyama H, Han K, Pantuck AJ, Belldegrun AS: Novel kidney cancer vaccine using dendritic cells transduced with recombinant adenovirus expressing carbonic anhydrase IX for the generation of a specific cytotoxic anti-tumor response. American Urological Association, Chicago, IL, 2003.
46. Singer J, Pantuck AJ, Zisman A, Figlin R, Belldegrun A, Gritsch HA: Long-term outcomes of renal cell carcinoma after kidney transplantation: the UCLA experience. American Society of Transplant Surgeons Winter Symposium, Miami, FL, January 24, 2003.
47. Langhorn C, Pantuck A, Leibovich B, Dorey F, Belldegrun AS: Cytogenetics of kidney cancer. Western Region American Federation for Medical Research. Carmel, CA. January 31, 2003.
48. Han KR, Bui MHT, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukoyama H, Figlin RA, and Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. Society of Urologic Oncology, Bethesda, MD, 2002.
49. Han K, Pantuck AJ, Slaton J, Mulders P, Swanson P, Zisman A, Figlin R, Belldegrun AS: The UCLA integrated staging system predicts survival in an international renal cell carcinoma population. Society of Urologic Oncology, Bethesda, MD, 2002.
50. Han K, Pantuck AJ, Shvarts O, Bui MH, Freitas D, Zisman A, Leibovich B, Dorey F, Gitlitz BJ, Figlin R, Belldegrun AS: Multiple metastatic sites rather than location dictates

overall survival of patients with metastatic renal cell carcinoma. Western Section American Urological Association, Hawaii, 2002.

51. Han K, Lugg J, Freitas D, Childs S, Cohen J, Zisman A, Zincke H, Pantuck AJ, Belldegrun A: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. Western Section American Urological Association, Hawaii, 2002.
52. Freedland S, Pantuck AJ, Paik S, Zisman A, Graeber T, Eisenberg D, McBride W, Dguyen D, Tso C, Belldegrun A: Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone refractory prostate cancer tumor system. Western Section American Urological Association, Hawaii, 2002.
53. Freedland S, Pantuck AJ, Paik S, Zisman A, Palotie A, Wieder J, Horvath S, Seligson D, Liu A, Nguyen D, Tso C, Belldegrun A: Loss of CD10 (endopeptidase) is a frequent and early event in human prostate cancer. Western Section American Urological Association, Hawaii, 2002.
54. Bui M, Seligson D, Han K, Pantuck AJ, Dorey F, Huang Y, Horvath S, Leibovich B, Chopra S, Liao S, Standbridge E, Lerman M, Palotie A, Figlin R, Belldegrun A: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma. Western Section American Urological Association, Hawaii, 2002.
55. Pantuck AJ, Lu Q, Zhang ZF, Belldegrun AS, Rao J: Chemoprevention of bladder cancer using green tea polyphenol extract: the effect of green tea on cell proliferation and F/G actin ratio. Cancer Integrative Medicine 1<sup>st</sup> International Conference. Chicago, IL, 2002.
56. Langhorn C, Pantuck AJ, Rao N, Dorey F, Leibovich B, Belldegrun AS: Cytogenetics of kidney cancer: correlating tumor karyotype with tumor histology and other clinical measures. UCLA Short Term Training Program. Los Angeles, 2002.
57. Zisman A, Sandbank J, Belldegrun AS, Schulam P, Cooper A, Pantuck AJ, Simon-Tov Y, Lindner A: Ultrathin, ultrashort, intracorporeally-manueverable cryoprobes for laparoscopic renal cryoablation in the porcine model. World Congress of Endourology, Milan, Italy, 2002.
58. Pantuck AJ, Zisman A, Chao D, Dorey F, deKernion JB, Figlin RA, Belldegrun AS: A comparison of Interferon versus Interleukin-2 following nephrectomy for metastatic renal cell carcinoma. American Society of Clinical Oncology, Orlando, 2002.
59. Han KR, Zisman A, Pantuck AJ, Freitas D, Bui M, Wieder J,

- Dorey F, Chao D, Gitlitz B, Figlin RA, Belldegrun AS: Renal cell carcinoma and prognostic significance of metastatic sites. American Society of Clinical Oncology, Orlando, 2002.
60. Zisman A, Pantuck AJ, Dorey F, Chao D, Said J, deKernion JB, Figlin RA, Belldegrun AS: Clinical outcome algorithm to predict the natural history of renal cell carcinoma in the era of aggressive cytoreductive nephrectomy and modern immunotherapy. American Society of Clinical Oncology, Orlando, 2002.
  61. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Gambhir S, Wu Lily, Belldegrun AS: CL1-SR39: a non-invasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. American Urological Association, Orlando, 2002.
  62. Pantuck AJ, Lu Q, Zhang ZF, Belldegrun AS, Rao J: Chemoprevention of bladder cancer using green tea polyphenol extract: the effect of green tea on cell proliferation and F/G actin ratio. American Urological Association, Orlando, 2002.
  63. Pantuck AJ, Zisman A, Chao D, Dorey F, Flanigan R, deKernion J, Figlin R, Belldegrun AS: Survival advantage of Interleukin-2 over Interferon immunotherapy when combined with cytoreductive nephrectomy based on SWOG 8949-matched populations. American Urological Association, Orlando, 2002.
  64. Zisman A, Pantuck AJ, Chao D, Dorey F, Said J, deKernion J, Figlin R, Belldegrun AS: Renal cell carcinoma with IVC extension: the role of nephrectomy, immunotherapy and the relevance of the 1997 TNM staging system. American Urological Association, Orlando, 2002.
  65. Zisman A, Pantuck AJ, Chao D, Dorey F, Said J, deKernion J, Figlin R, Belldegrun AS: UISS-based clinical algorithm to predict outcome of patients with localized and advanced renal cell carcinoma. American Urological Association, Orlando, 2002.
  66. Freedland SJ, Liu A, Pantuck AJ, Zisman A, Nguyen D, Tso CL, Paik S, Belldegrun AS: In vivo modeling of prostate cancer progression using a novel fluorescent-labeled, clonal tumor system. American Urological Association, Orlando, 2002.
  67. Hernandez J, Bui M, Han K, Pantuck AJ, Zisman A, Freitas D, Tso CL, Paik S, Belldegrun AS: Generation of a vaccine for renal cell carcinoma based on the fusion protein G250-GMCSF. American Urological Association, Orlando, 2002.
  68. Han K, Lugg J, Freitas D, Childs S, Cohen J, Miller R, Shuman

- B, Jayson M, Shore N, Moore Y, Zisman A, Zincke H, Pantuck AJ, Belldegrun AS: Treatment of organ-confined prostate cancer with third generation cryosurgery: preliminary multi-center experience. American Urological Association, Orlando, 2002.
69. Slaton J, Zisman A, Pantuck AJ, Belldegrun AS, Dinney C, Swanson D: Validation of UCLA integrated staging system (UISS) as a predictor for survival in patients undergoing nephrectomy for renal cell carcinoma. American Urological Association, Orlando, 2002.
70. Hernandez J, Bui M, Han K, Pantuck AJ, Zisman A, Freitas D, Tso CL, Paik S, Belldegrun AS: Generation of a vaccine for renal cell carcinoma based on the fusion protein GMCSF-G250. American Association for Cancer Research, San Francisco, 2002.
71. Lu Qingyi, Pantuck AJ, Jin J, Zhang Z, Belldegrun AS, Rao JY: Chemoprevention of bladder cancer using green tea polyphenol extracts—the effect of green tea on cell proliferation and F/G actin ratio. American Association for Cancer Research, San Francisco, 2002.
72. Rao JY, Seligson D, Visapaa H, Horvath S, Michel K, Pantuck AJ, Belldegrun AS, Palotie A: Tissue microarray analysis of cytoskeletal actin associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. American Association for Cancer Research, San Francisco, 2002.
73. Pantuck AJ, Belldegrun AS: Molecular in vivo imaging using GFP and MicroPET scanning. AACR New Discoveries in Prostate Cancer Biology and Treatment. Naples, FL, 2001.
74. Pantuck AJ, Zisman A, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: RCC with retroperitoneal lymph nodes: survival, response to immunotherapy, and role of lymph node dissection. Society of Urologic Oncology, Bethesda, 2001.
75. Freedland SJ, Pantuck AJ, Liu AY, Zisman A, Nguyen D, Tso CL, Belldegrun AS: Molecular and cellular analysis of the progression and heterogeneity of prostate cancer using a unique tumor system of fluorescence labeled, single cell clones. Western Section American Urological Association, Anchorage, Alaska, 2001.
76. Pantuck AJ, Zisman A, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Regional lymphadenopathy during cytoreductive nephrectomy predicts IL-2 failure in patients with metastatic renal cell carcinoma. American Society of Clinical Oncology, San Francisco, 2001.
77. Zisman A, Pantuck AJ, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: UISS: A novel integrated staging

system better predicts survival of patients with renal cell carcinoma. American Society of Clinical Oncology, San Francisco, 2001.

78. Pantuck A, Matherly J, Zisman A, Wu L, Belldegrun A: Second generation suicide gene therapy using herpes simplex virus thymidine kinase mutants for advanced prostate cancer. American Urological Association, Anaheim, 2001.
79. Belldegrun A, Zisman A, Pantuck AJ, Dorey F, Gitlitz B, deKernion JB, Figlin R: Cytoreductive nephrectomy and adjuvant immunotherapy significantly prolong life of patients with metastatic renal cell carcinoma. American Urological Association, Anaheim, 2001.
80. Zisman A, Pantuck AJ, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Should tumor size cut off point between RCC stages T1-1997 and T2-1997 be lowered? American Urological Association, Anaheim, 2001.
81. Zisman A, Pantuck AJ, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Improved prognostication using a novel integrated staging system for renal cell carcinoma. American Urological Association, Anaheim, 2001.
82. Belldegrun A, Pantuck AJ, Lohner M, Xiao-dong Y, Roskos L, Schwab G, Weiner L, Figlin R: A fully human anti-epidermal growth factor receptor (EGFr) antibody in patients with renal or prostate cancer. American Urological Association, Anaheim, 2001.

83. Pantuck AJ, Freeland SJ, Zisman A, Matherly J, Tso CL, Belldegrun AS: A fluorescence labeled, single-cell derived, metastatic tumor model for hormone refractory prostate cancer. American Association for Cancer Research, New Orleans, 2001.
84. Freeland SJ, Pantuck AJ, Tso CL, Zisman A, Matherly J, Belldegrun AS: Cellular and molecular characterization of the heterogeneity of hormone refractory CaP using a unique single cell derived and GFP expressing clonal tumor model. American Association for Cancer Research, New Orleans, 2001.
85. Zisman A, NG CP, Pantuck AJ, Tso CL, Bonavida B, Belldegrun AS: Actinomycin D and gencitabine synergistically sensitize androgen-independent prostate cancer cells to APO2/TRAIL mediated apoptosis. American Association for Cancer Research, New Orleans, 2001.
86. Pantuck AJ, Zisman A, Shvarts O, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Natural history and the role of nephrectomy in the biology of RCC: the UCLA experience. Western Section American Urological Association, Palm Desert, 2000.
87. Pantuck AJ, Zisman A, Tso CL, Belldegrun A: Pulsed androgen deprivation therapy: a modified schedule of intermittent androgen deprivation for advanced prostate cancer. Western Section American Urological Association, Palm Desert, 2000.
88. Pantuck AJ, Zisman A, Patel BJ, Tso CL, Belldegrun AS: An androgen independent, fluorescence tagged metastatic tumor model for hormone refractory metastatic prostate cancer. Western Section American Urological Association, Palm Desert, 2000.
89. Zisman A, Pantuck AJ, deKernion JB, Tso CL, Belldegrun AS: G250-GMCSF: a novel RCC specific tumor vaccine. Western Section American Urological Association, Palm Desert, 2000.
90. Zisman A, Pantuck AJ, Dorey F, Figlin R, Shvartz O, Quintana D, deKernion JB, and Belldegrun A: Improved prognostication for RCC using an integrated staging system. Western Section American Urological Association, Palm Desert, 2000.
91. Pantuck AJ, Zisman A, Shvarts O, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Natural history and the role of nephrectomy in the biology of RCC: the UCLA experience. American Society of Clinical Oncology, New Orleans, 2000.
92. Zisman A, Pantuck AJ, Patel BJ, Tso CL, Belldegrun AS: An androgen independent, fluorescence tagged metastatic tumor model for hormone refractory metastatic prostate cancer. American Association for Cancer Research, San Francisco,

2000.

93. Zisman A, Pantuck AJ, deKernion JB, Tso CL, Belldegrun AS: G250-GMCSF: a novel RCC specific tumor vaccine. American Urological Association, Atlanta, 2000.
94. Pantuck AJ, van Ophoven A, Gitlitz B, Tso CL, Stiles A, Acres B, Ross M, Figlin R, Belldegrun A: MUC-1/IL-2 gene therapy for advanced prostate cancer: phase I trial and clinical reponse associated systemic immune activation. American Urological Association, Atlanta, 2000.
95. Zisman A, Pantuck AJ, Patel BJ, Tso CL, Belldegrun A: CL1-GFP: a novel hormone refractory and metastatic prostate cancer model tagged with green fluorescence. American Urological Association, Atlanta, 2000.
96. Pantuck AJ, Van Ophoven A, Tso CL, Stiles A, Acres B, Ross M, Figlin R, Belldegrun AS: Phase 1 clinical trial for advanced prostate cancer using a recombinant vaccinia virus expressing MUC-1 and IL-2 genes. Western Section American Urological Association, Monterey, 1999.
97. Pantuck AJ, Murphy DP, Amenta PS, Das KM, Cummings KB, Keaney G, Weiss RE: Female urethral adenocarcinoma: immunohistochemical evidence for more than one tissue of origin. Western Section American Urological Association, Monterey, 1999.
98. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Bedani K, Pantuck AJ, Weiss RE, Cummings KB: Cancer detection with endorectal magnetic resonance imaging in men with elevated serum prostate specific antigen levels and prior negative biopsies. American College of Surgeons, San Francisco, 1999.
99. Murphy DP, Pantuck AJ, Amenta PS, Das KM, Cummings KB, Keaney G, Weiss RE: Female urethral adenocarcinoma: an immunohistochemical study. American College of Surgeons, San Francisco, 1999.
100. Pantuck AJ, Han KR, Perrotti M, Weiss RE, Cummings KB: Uretero-intestinal implantation in continent urinary diversion: long term results and complications of refluxing versus non-refluxing techniques. American Urological Association, Dallas, 1999.
101. Pantuck AJ: Inflammation, intestinal metaplasia and adenocarcinoma of the lower genitourinary system. The Philadelphia Urological Society, Philadelphia, 1998.
102. Pantuck AJ, Murphy DP, Amenta PS, Das KM, Cummings KB, Weiss RE: The monoclonal antibody 7E12H12 can differentiate primary adenocarcinoma of the bladder and prostate. American Urological Association, San Diego, 1998.

103. Pantuck AJ, Bancila E, Das K, Amenta PS, Cummings KB, Marks M, Weiss RE: Adenocarcinoma of the urachus and urinary bladder express a unique colonic epithelial epitope: An immunohistochemical study. Cancer Institute of New Jersey, Princeton, 1997.
104. Pantuck AJ: Adenocarcinoma of the Urachus and Bladder express a unique colonic epithelial epitope: An immunohistochemical study. The New York Section of the American Urologic Association, Valentine Urology Residents Essay Meeting, New York, 1997.
105. Kraus SR, Villanueva J, Weiss RE, Pantuck AJ, Gwodz P, Sleat D, Lobel P, Raska K, Cummings KB: Mannose 6 phosphorylated glycoproteins in prostate adenocarcinoma: A predictor of PSA elevation after radical prostatectomy, American Urological Association, New Orleans, 1997.
106. Cummings KB, Sarvazyan AP, Pantuck AJ, Ward SW, Weiss RE: Mechanical Imaging: A novel device for prostate imaging, American Urological Association, New Orleans, 1997.
107. Weiss RE, Sarvazyan AP, Fishman V, Pantuck AJ, Ward SW, Cummings KB: Development of a database for three dimensional imaging of prostate disease, American Urological Association, New Orleans, 1997.
108. Villanueva J, Kraus S, Pantuck AJ, Weiss R, Sleat D, Cummings K, Lobel P, Raska K: Mannose 6-Phosphate Glycoproteins in prostate carcinoma: A new marker for post operative rise in serum PSA? American Society of Clinical Pathologists, 1997.
109. Pantuck AJ, Lobis MR, Barone JG, Mezrich RT, Cummings KB: Increased Detection of Prostate Cancer Using MRI Guided Ultrasound Biopsies, American College of Surgeons, Chicago, 1994.
110. Pantuck AJ, Barone JG, Lobis MR, Cummings KB: Is MRI Useful for the Patient With an Elevated PSA Density and a Negative Biopsy? Cancer Institute of New Jersey, Princeton, 1993.
111. Benson MC, Whang IS, Pantuck AJ, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. American Urological Association, Toronto, 1991.
112. Pantuck AJ: Tumor Cell Heterogeneity in a Human Epidermal Carcinoma Cell Line. Department of Chemical Biology and Pharmacognosy, Rutgers University, Piscataway, NJ 1988.

**Video Presentations:**

1. Cummings KB, Pantuck AJ, Glazier DB: Nerve-sparing radical retropubic prostatectomy: refining the anatomic approach. American Urological Association, Anaheim, 2001.
2. Zisman A, Pantuck AJ, Cohen J, Belldegrun A: Cryosurgical ablation of the prostate. UCLA State of the Art, Marina del Rey, 2001.
3. Pantuck AJ, Zisman A, Cohen J, Belldegrun A: Cryosurgical ablation of renal tumors using ultra-thin cryo-probes. UCLA State of the Art, Marina del Rey, 2001.
4. Cummings KB, Pantuck AJ, Glazier DB: Nerve-sparing radical retropubic prostatectomy: refining the anatomic approach. American College of Surgeons, New Orleans, 2001.
5. Zisman A, Pantuck AJ, Cohen J, Belldegrun A: Cryosurgical ablation of the prostate. 19<sup>th</sup> World Congress on Endourology and shockwave and basic research symposium and exhibition, Bangkok, 2001.
6. Pantuck AJ, Zisman A, Cohen J, Belldegrun A: Cryosurgical ablation of renal tumors using ultra-thin cryo-probes. 19<sup>th</sup> World Congress on Endourology and shockwave and basic research symposium and exhibition, Bangkok, 2001.
7. Pantuck AJ, Weider J: Lidocaine nerve block for TRUS guided prostate biopsy. UCLA State of the Art, 2003.
8. Zisman A, Pantuck AJ, Chao D, Schulam P, Belldegrun AS: Laparoscopic cryoablation of renal tumors. UCLA State of the Art, 2003.

## PUBLICATIONS

### REVIEWED PAPERS:

1. Benson MC, Whang IS, Pantuck AJ, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. Journal of Urology, 147:815-816, 1992.
2. Barone JG, Pantuck AJ, Difazio LT, Cummings KB: Perforated Duodenal Diverticulum Following Renal Surgery. Infections in Urology, 7:143-146, 1994.
3. Pantuck AJ, Lobis MR, Barone JG, Mezrich RT, Cummings KB: Increased Detection of Prostate Cancer Using MRI Guided Ultrasound Biopsies. Surgical Forum Volume XLV, 817-819, 1994.
4. Pantuck AJ, Barone JG, Cummings KB: Vena Cava Resection

during Post Chemotherapy Lymphadenectomy for Testis Tumor. American Surgeon, 61:424-426, 1995.

5. Pantuck AJ, Barone JG, Rosenfeld RD, Fleisher MH: Occult Bilateral Ectopic Vaginal Ureters Causing Urinary Incontinence: Diagnosis by Computed Tomography. Abdominal Imaging, 21:78-80, 1996.
6. Pantuck AJ, Lobis MR, Ciocca R, Weiss RE: Penile replantation using the leech *Hirudo medicinalis*. Urology, 48:953-956, 1996.
7. Pantuck AJ, Barone JG, Amenta PS, Smilow P, Cummings KB: Diagnosis and management of malignant perirenal schwannoma. American Surgeon, 62:1024-1027, 1996.
8. Pantuck AJ, Goldsmith JW, Kuriyan JB, Weiss RE: Seizures after ureteral stone manipulation with lidocaine. Journal of Urology, 157:2248, 1997.
9. Pantuck AJ, Weiss RE, Cummings KB: Routine stentograms are not necessary prior to stent removal following radical cystectomy. Journal of Urology, 158:777-777, 1997.
10. Pantuck AJ, Bancila E, Das K, Amenta PS, Cummings KB, Marks M, Weiss RE: Adenocarcinoma of the urachus and urinary bladder express a unique colonic epithelial epitope: An immunohistochemical study. Journal of Urology, 158:1772-1777, 1997.

11. Pantuck AJ, Kraus SR, Barone JG: Hair strangulation injury of the penis. Pediatric Emergency Care, 13:423-425, 1997.
12. Pantuck AJ, Fleisher MH, Barone JG: Genital hair strangulation in an uncircumcised boy. The Canadian Journal of Urology, 4:455, 1997.
13. Pantuck AJ, Vates TQ, Javidian P, Weiss RE: Urachal Adenocarcinoma. The Canadian Journal of Urology, 4:450-452, 1997.
14. Pantuck AJ, Barone JG: Polyorchidism in an 11 year old boy. Infections in Urology, 11:37-41, 1998.
15. Pantuck AJ, Murphy DP, Das KM, Amenta PS, Cummings KB, Weiss RE: The monoclonal antibody 7E<sub>12</sub>H<sub>12</sub> can differentiate primary adenocarcinoma of the bladder and prostate. The British Journal of Urology, 82:426-430, 1998.
16. Han KR, Siegel R, Pantuck AJ, Gazi MA, Burno DK, Weiss RE: Behcet's syndrome with left ventricular aneurysm and ruptured renal artery pseudoaneurysm. Urology, 54:162, 1999.
17. Murphy DP, Pantuck AJ, Amenta PS, Das KM, Cummings KB, Keaney G, Weiss RE: Female urethral adenocarcinoma: Immunohistochemical evidence for more than one tissue of origin. The Journal of Urology, 161:1881-1884, 1999.
18. Pantuck AJ, Li RZ, Perrotti M: Stamey needle passage of fascial pubovaginal sling after failed vesicourethroplasty. Techniques in Urology, 5:21-23, 1999.
19. Han KR, Goldstein DW, Pantuck AJ, Marmar JL, Lobby N: Angiographic management of pseudoaneurysm and arteriocalyceal fistula following blunt trauma: case report and review of the literature. The Canadian Journal of Urology, 5:654-657, 1999.
20. Han KR, Pantuck AJ, Siegel R, Ciocca RG, Noshier JL, Cummings KB, Perrotti M: Endovascular stent graft for management of ureteroarterial fistula after orthotopic bladder substitution. Techniques in Urology, 5:169-173, 1999.
21. Han KR, Pantuck AJ, Lobby NJ, Marmar JL: Signet ring cell carcinoma of the prostate: case report and review of the literature. The Prostate Journal, 1:144-145, 1999.

22. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Bedani K, Pantuck AJ, Weiss RE, Cummings KB: Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy. A pilot study. The Journal of Urology, 162:1314-1317, 1999.
23. Murphy DP, Pantuck AJ, Amenta PS, Das KM, Cummings KB, Keeney GL, Weiss RE: Female urethral adenocarcinoma: an immunohistochemical study. Surgical Forum Volume, 1999.
24. Perrotti M, Han KR, Epstein RE, Kennedy EC, Rabbani F, Bedani K, Pantuck AJ, Weiss RE, Cummings KB: Cancer detection with endorectal magnetic resonance imaging in men with elevated serum prostate specific antigen levels and prior negative biopsies. Surgical Forum Volume, 1999.
25. Perrotti M, Pantuck AJ, Israeli RS, Rabbani F, Cummings KB, Weiss RE: A review of staging modalities for clinically localized prostate cancer. Urology, 54:208-214, 1999.
26. Pantuck AJ, Han KR, Perrotti M, Weiss RE, Cummings KB: Ureteroenteric anastomosis in continent urinary diversion: long term results and complications of direct versus non-refluxing techniques. The Journal of Urology, 163:450-455, 2000.
27. Han KR, Pantuck AJ, Kulzer LM, Tao Y, Kraus SR: Testicular infarction associated with chronic lymphocytic leukemia. The British Journal of Urology International 86(1):144, 2000. Available from <http://dx.doi.org>.
28. Murphy DP, Pantuck AJ, Perrotti M: Multiple percutaneous drainage in the acute management of septic loculated renal abscess. Infections in Urology, 14:95-97, 2000.
29. Pantuck AJ, Fleisher MH, Barone JG: Pyelonephritis complicating a multicystic dysplastic kidney. Infections in Urology, 13:16-17, 2000.
30. Raheja R, Pantuck AJ, Fleisher MH: Diagnostic doppler scrotal ultrasound for acute scrotal pain: Bacterial epididymitis is misleading. Infections in Urology 13:121-123, 2000.
31. Patel B, Pantuck AJ, Zisman A, Tso CL, deKernion J, Belldegrun A: CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. The Journal of Urology, 164:1420-1425, 2000.

32. Pantuck AJ, Zisman A, Tso CL, Belldegrun A: Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate Cancer and Prostatic Diseases, 3:280-282, 2000.
33. Zisman A, Pantuck AJ, Belldegrun A: Gene and immune-based therapies for genitourinary malignancies: current status and future prospects. The Journal of the Israeli Medical Association, 2:33-42, 2000.
34. Pantuck AJ, Zisman A, Rauch M, Belldegrun AS: Incidental renal tumors. Urology, 56:190-196, 2000.
35. Pantuck AJ, Zisman A, Belldegrun AS: Gene therapy for prostate cancer at UCLA: initial results and future directions. World Journal of Urology, 18:143-147, 2000.
36. Gazi M, Pantuck AJ, Ankem M, Han KR, Barone JG: Management of penile toilet seat trauma. Canadian Journal of Urology, 8:1293-1294, 2001.
37. Zisman A, Pantuck AJ, Dorey F, Figlin R, Shvartz O, Quintana D, deKernion JB, and Belldegrun A: Improved prognostication for RCC using an integrated staging system. Journal of Clinical Oncology, 15:1649-1657, 2001.
38. Belldegrun A, Bander NH, Lerner SP, Woods DP, Pantuck AJ: The Society of Urological Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. The Journal of Urology, 166:1316-1321, 2001.
39. Zisman A, Chuen-Pei NG, Pantuck AJ, Bonavida B, Belldegrun AS: Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to APO2L/TRAIL-mediated apoptosis. Journal of Immunotherapy, 24:459, 2001.
40. Zisman A, Pantuck AJ, Dorey F, Chao D, Said JW, Gitlitz BJ, deKernion JB, Figlin R, Belldegrun AS: Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. Journal of Urology, 166:54-58, 2001.
41. Bui Matthew, Zisman A, Pantuck AJ, Han KR, Wieder J, and Belldegrun AS: Prognostic Factors and Molecular Markers for Renal Cell Carcinoma. Expert Reviews in Anticancer Therapy, 1:89-99, 2001.

42. Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R: Interleukin 2 (IL-2) gene therapy for prostate cancer: Phase I clinical trial and basic biology. Human Gene Therapy 12:883-892, 2001.
43. Tso CL, Zisman A, Pantuck A, Hernandez J, Paik S, Calilli R, Nguyen D, Shintaku PI, deKernion J, Figlin R, Belldegrun A: Induction of G250 Targeted and T- Cell Mediated Anti-tumor activity Against Renal Cell Carcinoma Using a Chimeric Fusion Protein Consisting of G250 and Granulocytes-Monocyte Colony Stimulating Factor. Cancer Research, 61:7925-7933, 2001.
44. Pantuck AJ, Zisman A, Belldegrun AS: Immune and gene therapy for renal cell carcinoma. International Journal of Urology, 8(7):S1-4, 2001.
45. Pantuck AJ, Zisman A, Henderson H, Wilson D, Schreiber A, Belldegrun A: New biologicals for prostate cancer prevention: genes, vaccines and immune-based interventions. Urology, 4:95-99, 2001.
46. Zisman A, Pantuck AJ, Cohen J, Belldegrun A: Prostate cryoablation using direct transperineal placement of ultra-thin probes through a 17 gauge brachytherapy template. Technique and preliminary results. Urology, 58:988-993, 2001.
47. Chao D, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Figlin R, Belldegrun A: Collecting duct renal cell carcinoma: clinical study of a rare tumor. Journal of Urology, 167:71-74, 2001.
48. Weider J, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS: Update on gene and immune based therapy for urologic malignancy. Urologic Oncology, 6:265-275, 2001.
49. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. Journal of Urology, 166:1611-1623, 2001.
50. Chao D, Zisman A, Freedland S, Pantuck AJ, Said J, Belldegrun A: Sarcomatoid renal cell carcinoma: basic biology, clinical behavior and response to therapy. Urologic Oncology, 6:231-238, 2001.
51. Pantuck AJ, Zisman A, Belldegrun AS: Basic biology of renal cell carcinoma: changing concepts in classification and staging. Seminars in Urologic Oncology, 19:72-79, 2001.

52. Zisman A, Pantuck AJ, Belldegrun AS, Schulam P: Laparoscopic radical nephrectomy. Seminars in Urologic Oncology, 19:114-122, 2001.
53. Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS: Validation of the UCLA Integrated Staging System for renal cell carcinoma. Journal of Clinical Oncology, 19:3792-3793, 2001.
54. Pantuck AJ, Belldegrun AS, Figlin RA: A comparison of interferon versus interleukin-2 following nephrectomy for metastatic renal cell carcinoma. New England Journal of Medicine, 345:1711-1722, 2001.
55. Pantuck AJ, Matherly J, Zisman A, Berger F, Black M, Gambhir S, Belldegrun AS, Wu L: Optimizing prostate cancer suicide gene therapy using Herpes Simplex Virus Thymidine Kinase gene mutants. Human Gene Therapy, 13:777-789, 2002
56. Chao D, Zisman A, Pantuck AJ, Said J, Belldegrun A: Oncocytoma: diagnosis and clinical behavior. Urology, 59:635-642, 2002.
57. Pantuck AJ, Han K, Belldegrun AS, Rao JY: Tumor markers for the early detection of bladder cancer. Frontiers in Bioscience, 7:19-26, 2002.
58. Zisman A, Pantuck AJ, Dorey F, Chao D, Gitlitz BJ, Lazarovici D, deKernion JB, Figlin R, Belldegrun AS: A mathematical model to predict individual survival for patients with renal cell carcinoma. Journal of Clinical Oncology, 20:1368-1374, 2002.
59. Pantuck AJ, Zisman A, Cohen J, Belldegrun A: Cryosurgical ablation of renal tumors using 1.5 mm., ultra-thin cyroprobes. Urology, 59:130-133, 2002.
60. Pantuck AJ, Berger F, Zisman A, Tso CL, Nguyen D, Matherly J, Gambhir S, Wu L, Belldegrun AS: CL1-SR39: molecular-based PET imaging of a prostate cancer tumor xenograft model. Journal of Urology, 168:1193-1198, 2002.
61. Zisman A, Pantuck AJ, Chao D, Dorey F, Wieder J, Said JW, deKernion JB, Belldegrun AS: Renal cell carcinoma with tumor thrombus extension: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? Journal of Urology, 168:962-967, 2002.

62. Chao D, Zisman A, Pantuck AJ, Kim HJ, Wieder J, Figlin RA, Said JW, Belldegrun AS: Unclassified renal cell carcinoma: clinical features and prognostic impact of new histologic subtype. Journal of Urology, 168:950-955, 2002.
63. Rao JY, Seligson D, Visapaa H, Horvath S, Gaber F, Michel K, Pantuck AJ, Belldegrun A, Palotie A: Tissue array analysis of cytoskeletal actin-associated proteins Gelsolin and E-Cadherin in urothelial cancer. Cancer, 15:1247-1257, 2002.
64. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS: Positron emission tomography in urologic oncology. Cancer Control. 9:335-342, 2002.
65. Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE, Pantuck AJ, Tyler VE: PC-SPES: herbal formulation for prostate cancer. Urology, 60:369-375, 2002.
66. Zisman A, Pantuck AJ, Dorey F, Chao D, Said JW, Gitlitz BJ, deKernion JB, Figlin R, Belldegrun AS: A simplified integrated staging system for renal cell carcinoma: high, intermediate, and low risk. Journal of Clinical Oncology, 20:4559-4566, 2002.
67. Perry K, Zisman A, Gritsch A, Pantuck AJ, deKernion J, Schulam P: The use of heparin and protamine sulfate in conjunction with laparoscopic donor nephrectomy. Transplantation, 27:1700-1702, 2002.
68. Zisman A, Pantuck AJ, Chao D, Dorey F, Han K, Said JW, Figlin R, deKernion JB, Belldegrun AS: The role of nephrectomy, immunotherapy and the 1997 TNM staging system in renal cell carcinoma with gross tumor thrombus extension. Journal of Urology, 169:909-916, 2003.
69. Han K, Pantuck AJ, Bui M, Shvarts O, Freitas D, Zisman A, Leibovich B, Dorey F, Gitlitz B, Figlin R, Belldegrun: TNM T3a renal cell carcinoma: adrenal invasion is not the same as renal fat invasion. The Journal of Urology, 169:899-904.
70. Bui M, Seligson D, Han KR, Pantuck AJ, Dorey F, Huang Y, Horvath S, Leibovich B, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clinical Cancer Research, 9:802-811, 2003.

71. Han K, Pantuck AJ, Bui M, Shvarts O, Freitas D, Zisman A, Leibovich B, Dorey F, Gitlitz B, Figlin R, Belldegrun: Number of Metastatic Sites Rather than Location Dictates Overall Survival of Patients with Node Negative Metastatic Renal Cell Carcinoma. Urology, 61:314-319, 2003.
72. Freedland S, Seligson D, Liu A, Pantuck AJ, Horvath S, Wieder J, Zisman A, Nguyen D, Tso CL, Palotie A, Belldegrun AS: Loss of CD10 (neutral endopeptidase) is a frequent and early event in prostate cancer. Prostate, 55:71-80, 2003.
73. Vispaa H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck AJ, Figlin R, Rao J, Belldegrun AS, Horvath S, Palotie A: Correlation of Ki67 and Gelsolin expression to clinical outcome in renal cell carcinoma. Urology, 61:845-850, 2003.
74. Freedland S, Pantuck AJ, Paik S, Zisman A, Graeber T, David Eisenberg, McBride W, Nguyen D, Tso C, and Belldegrun AS: Heterogeneity of Molecular Targets on Clonal Cancer Lines Derived From a Novel Hormone-Refractory Prostate Cancer Tumor System. Prostate, 55(4):299-307, 2003.
75. Pantuck AJ, Zisman A, Chao D, Dorey F, Han K, Gitlitz B, Figlin RA, Belldegrun AS: Retroperitoneal lymph node dissection improves survival in patients with metastatic renal cell carcinoma. Journal of Urology, 169:2076-2083, 2003.
76. Pantuck AJ: Cytoreductive Nephrectomy Improves Survival in Metastatic Kidney Cancer: Caveats and Mechanisms. Oncology, 17:705-711, 2003.
77. Pantuck AJ, Zisman A, Chao D, Dorey F, Figlin RA, Belldegrun AS: Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer, 97:2995-3002, 2003.
78. Pantuck AJ, Gitlitz BJ: Renal Cell Carcinoma module. American College of Physicians Physician Education and Information Resource, <http://pier.acponline.org/index.html>.
79. Zisman A, Pantuck AJ, Bui M, Said J, Caliliw R, Rao N, Shintaku P, Berger F, Gambhir S, Belldegrun A: LABAZ1: a metastatic tumor model for chromophil (papillary) non-hereditary type 2 renal cell carcinoma expressing CA IX. Cancer Research, 63:4952-4959, 2003.

80. Leibovich B, Pantuck AJ, Bui M, Han K, Zisman A, Figlin R, Belldegrun AS: Staging and prognosis of renal cell carcinoma. Urologic Clinics of North America, 30:481-497, 2003.
81. Han KR, Cohen J, Miller R, Pantuck AJ, Freitas DG, Cuevas CA, Kim H, Lugg J, Childs S, Shuman B, Jayson M, Shore N, Moore Y, Zisman A, Lee J, Ugarte R, Zincke H, Belldegrun A: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multi-center experience. The Journal of Urology, 170:1126-1130, 2003.
82. Gitlitz BJ, Belldegrun AS, Zisman A, Chao D, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA: A pilot trial of tumor lysate loaded dendritic cells for the treatment of metastatic renal cell carcinoma. Journal of Immunotherapy, 26:412-419, 2003.
83. Pantuck AJ, Zeng G, Belldegrun A, Figlin R: Pathobiology, Prognosis and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway. Clinical Cancer Research, 9:4641-4652, 2003.
84. Han K, Bleumer I, Pantuck AJ, Kim H, Dorey F, Zisman A, Janzen N, de Mulder PHM, Dinney C, Wood C, Swanson D, Figlin R, Mulders PFA, Belldegrun A: Validation of an Integrated Staging System Towards Improved Prognostication of Patients with Localized Renal Cell Carcinoma in an International Population. The Journal of Urology, 170:2221-2224,2003.
85. Leibovich BC, Han KR, Bui M, Pantuck AJ, Dorey F, Figlin RA, Belldegrun AS: Scoring algorithm to predict survival after nephrectomy and immunotherapy for metastatic RCC: a stratification tool for prospective clinical trials. Cancer, 98:2566-2575, 2003.
86. Janzen N, Laifer-Narin S, Han K, Seltzer M, Thomas A, Pantuck AJ, Belldegrun AS: Emerging technologies in Uroradiologic imaging. Urologic Oncology, 21(5):317-26, 2003.
87. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Fujioka T, Mori M, Kim W, Song J, Pantuck AJ: Comparison of percent equal producer between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean, and American residents. Japanese Journal of Clinical Oncology, 34:86-69,2004.

88. Pantuck AJ, Gitlitz B, van Ophoven A, Tso C, Acres B, Ross M, Belldegrun A, Figlin R: Phase I Trial of a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in Advanced Prostate Cancer: Immunologic modulation mediated Therapeutic Response. Journal of Immunotherapy, 27:240-253, 2004.
89. Seligson D, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui M, Han K, Correa A, Eeva M, Tze S, Palotie A, Figlin R, Belldegrun AS: EpCAM (KSA) is an independent predictor of survival in renal cell carcinoma. Clinical Cancer Research, 10:2659-2669, 2004.
90. Han K, Kim H, Pantuck AJ, Dorey F, Figlin R, Belldegrun AS: The use of the American Society of Anesthesiologists Score to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology, 63:841-846, 2004.
91. Jean-Jacques Patard, Oleg Shvarts, Allan J Pantuck, Hyung L Kim, Vincenzo Ficarra, Luca Cindolo, Ken-ryu Han, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, Dominique K Chopin, Robert A Figlin, Peter FA Mulders, Arie S Belldegrun: Safety and Efficacy of Partial Nephrectomy for all T1 Tumors Based on an International Multicenter Experience. Journal of Urology, 171:2181-2185, 2004.
92. Pantuck AJ: Review of Contemporary Management of Prostate Cancer with Lethal Potential. Oncology, 18:820-828, 2004.
93. Lam J, Shvarts O, Pantuck AJ: Changing Concepts in the Surgical Management of Renal Cell Carcinoma. European Urology, 45:692-705, 2004.
94. Jean-Jacques Patard, Hyung L Kim, Frederick Dorey, Allan J Pantuck, Amnon Zisman, Luca Cindolo, Ken-ryu Han, Vincenzo Ficarra, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Colin P Dinney, Christopher G Wood, David A Swanson, Claude C Abbou, Bernard Lobel, Robert A Figlin, Peter FA Mulders, Dominique K Chopin, Arie S Belldegrun: The value of the UISS (UCLA integrated staging system) in predicting survival in renal cell carcinoma: an international study in 4202 patients. Journal of Clinical Oncology, 15; 22(16):3316-22, 2004.
95. Han K, Janzen N, McWhorter V, Kim H, Pantuck AJ, Zisman A, Figlin R, Said J, Belldegrun AS: Cystic renal cell carcinoma: biology and clinical behavior. Urologic Oncology, 22:410-414, 2004.
96. Jean-Jacques Patard, Frederick J Dorey, Oleg Shvarts, Luca Cindolo, Vincenzo Ficarra, Alexandre De La Taille, Jacques

- Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, François Guillé, Dominique K Chopin, Robert A Figlin, Peter FA Mulders, Arie S Belldegrun, Allan J Pantuck. Symptoms as well as tumor size provide prognostic information on patients with. Journal of Urology, 172:2167-2171, 2004.
97. Zeng G, Aldridge M, Wang Y, Pantuck AJ, Wang A, Liu Y, Han Y, Yuan Y, Robbins P, Dubinett S, deKernion JB, and Belldegrun AS: A Dominant B Cell Epitope from NY-ESO-1 Recognized by Sera from a Wide Spectrum of Cancer Patients: Implications as a Potential Biomarker.
  98. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin RA, Belldegrun A, Pantuck AJ: p53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized renal cell carcinoma. Journal of Urology, 173:725-728, 2005.
  99. Lam J, Pantuck AJ, Belldegrun A, Figlin R: G250: A Carbonic Anhydrase IX Monoclonal Antibody. Current Oncology Reports 7:109-15, 2005.
  100. Lu Q, Jin Y, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, and Rao J: Green Tea Extract Modulates Actin Remodeling in an *in vitro* Multistep Carcinogenic Model via Rho Activity. Clinical Cancer Research, 11(4):1675-83, 2005.
  101. Jean-Jacques Patard, Nathalie Rioux-Leclercq, Luca Cindolo, Vincenzo Ficarra, Ken-ryu Han, Alexandre De La Taille, Jacques Tostain, Walter Artibani, Claude C Abbou, Bernard Lobel, Guillé François, Rioux-Leclercq Nathalie, Dominique K Chopin, Peter FA Mulders, Christopher G Wood, Robert A Figlin, Arie S Belldegrun and Allan J Pantuck. The prognostic value of histologic subtypes in Renal Cell Carcinoma (RCC). A multicenter experience in 4063 patients. Journal of Clinical Oncology, 23(12):2763-71, 2005.
  102. Shvarts O, Said J, Lam J, Pantuck AJ, Seligson D, Aldridge M, Bui M, Liu X, Horvath S, Belldegrun A: Clinical, pathological, and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer, 103:2517-2525, 2005.

103. Shvarts O, Lam J, Pantuck AJ, Figlin R, and Belldegrun A: Postoperative Surveillance Protocol for Patients with Localized and Locally Advanced Renal Cell Carcinoma Based on a Validated Prognostic Nomogram and Risk Group Stratification System. Journal of Urology, 174:466-472, 2005.
104. Leppert JT, Lam JS, Pantuck AJ, Figlin RA and Belldegrun AS: Carbonic Anhydrase IX and the Future of Molecular Markers in Renal Cell Carcinoma. BJU Int, Aug;96(3):281-5, 2005.
105. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken W, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann T: Gene Signatures of Progression and Metastasis in Renal Cell Cancer. Clin Cancer Res, Aug 15;11(16):5730-9, 2005.
106. Mestas J, Burdick M, Reckamp K, Pantuck AJ, Figlin RA, Strieter RM: The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. Journal of Immunotherapy, 175:5351-5357, 2005.
107. Cao W, Cai L, Rao J, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Cardo C, Belldegrun A, Zhang AF: Tobacco Smoking, GSTP1 Polymorphism and Bladder Cancer. Cancer, 104(11):2400-2408. 2005.
108. Leppert JT, and Pantuck AJ: The Significance of Gene Expression Analysis of Renal Cell Carcinoma. Expert Reviews in Anti-Cancer Therapy, 6(2), 293-299, 2006.
109. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun A, Pantuck AJ: Chemoprevention of Bladder Cancer. European Urology, 49:226-234, 2006.
110. Lam JS, Belldegrun AS, and Pantuck AJ: Long-Term Outcomes of the Surgical Management of Renal Cell Carcinoma. World Journal Of Urology, 2006.
111. Pantuck AJ, Leppert J, Zomorodian N, Seeram N, Aronson W, Seiler D, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A: Pomegranate juice for men with prostate cancer and a rising serum prostate specific antigen level after primary therapy: pre-clinical data and phase II clinical trial. Clinical Cancer Research, 12:4018-4026, 2006.
112. Lam J, Yu H, Li A, Eeva M, Leppert J, Shvarts O, Pantuck AJ, Horvath S, Seligson D, Belldegrun AS: Flap Endonuclease 1 is Overexpressed and Associated with High Gleason Score in Prostate Cancer. BJU International, 2006 Aug;98(2):445-51.

113. Jin Y, Iwata K, Belldegrun A, Figlin RA, Pantuck AJ, Zhang Z, and Rao J: Effect of an oral Epidermal Growth Factor Receptor Tyrosine Kinase inhibitor on Actin Remodeling in a Multistep Bladder Cancer Carcinogenesis Model. Molecular Cancer Therapeutics. 2006 Jul;5(7):1754-63.
114. Hung RJ, Zhang ZF, Rao JY, Pantuck A, Reuter VE, Heber D, Lu QY: Protective effects of plasma carotenoids on the risk of bladder cancer. Journal of Urology. 2006 Sep;176(3):1192-7.

**REVIEWED PAPERS IN PRESS:**

1. Pantuck AJ: Editorial. European Urology.
2. Shuch B, Shvarts O, Pantuck AJ: Post-nephrectomy kidney cancer surveillance protocols. UpToDate, 2006.
3. Pantuck AJ, Belldegrun AS, Figlin RA: Cyto-reductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is it Still Imperative in the Era of Targeted Therapy? Clinical Cancer Research.
4. Pantuck AJ, Thomas G, Belldegrun AS, and Figlin RA: mTOR inhibitors in renal cell carcinoma: current status and future applications. Seminars in Oncology.
5. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA and Pantuck AJ: p21 is a Prognostic Marker in Renal Cell Carcinoma: Implications for Novel Therapeutic Approaches. Journal of Urology.
6. Leppert JT and Pantuck AJ: Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation? Nature Clinical Practice Urology.

**REVIEWED PAPERS SUBMITTED FOR PUBLICATION:**

1. Pantuck AJ, Elashoff R, Wang H, Lieberman R, Figlin R, Belldegrun AS: Study design for phase II trial of erlotinib and green tea polyphenol to prevent the recurrence of tobacco-related, superficial bladder cancer.
2. Zisman A, Han K, Pantuck AJ, Dorey F, Bui M, Chao D, deKernion J, Said J, Belldegrun AS: Is chromophobe renal cell carcinoma associated with a more favorable prognosis?

3. Lu Qingyi, Pantuck AJ, Jin J, Zhang Z, Belldegrun AS, Rao JY: Chemoprevention of bladder cancer using green tea polyphenol extracts—the effect of green tea on cell proliferation and F/G actin ratio.
4. Jones J, Spentzos D, Out H, Aivado M, Kolia S, Paullus J, Belldegrun A, Figlin R, Pantuck AJ\*\*(co-senior author), Libermann T\*\*: Proteomic Identification of IL-2 Responders in Metastatic Renal Cell Carcinoma.
5. Xiao G, Jin Y, Lu Q, Zhang ZF, Belldegrun A, Figlin R, Pantuck AJ, Yen Y, Rao JY: Annexin-I as a Target Protein for Green Tea Extract Induced Actin Remodeling.
6. Bublik M, Sercarz J, Pantuck A, Blackwell KE, Richard Koya, analis R, Castro DJ, Paiva MB: Combined Cytoreductive Laser Therapy and Immunotherapy for Palliation of Metastatic Renal Cell Carcinoma to the Head and Neck.
7. Pantuck AJ, Fang X, Liu X, Seligson D, Horvath S, Leppert J, Belldegrun A, Figlin R: Gene Expression and Tissue Microarray Analysis of Interleukin-2 Complete Responders in Patients with Metastatic Renal Cell Carcinoma.
8. Glode LM, Pantuck AJ, Higano CS, Meyer J, Berenson RJ, Frohlich MW: A PHASE I/II TRIAL OF CD3/CD28-ACTIVATED T CELLS (XCELLERATED™ T CELLS) IN PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER.
9. Hung JC, Lu QY, Rao JY, Pantuck A, Reuter VE, Cordon-Cardo C, Scher HI, Figlin RA, Belldegrun AS, Heber D, Zhang ZF. Protective effects of plasma carotenoids on the risk of bladder cancer.
10. Yang Y, Lu M, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Scher H, Figlin RA, Belldegrun A, Cordon-Cardo C, Zhang ZF: The Role of *FGFR4* Polymorphism in the Progression of Bladder Cancer.
11. Seeram NP, Henning SM, Adams LS, Zhang L, Suchard M, Pantuck AJ, An Z, Morrison KJM, Jakobovits A, Aronson W, Belldegrun A, Li Z, and Heber D: Pomegranate Juice is Converted to Active Metabolites in Humans, Inhibits Prostate Cancer Cell Proliferation, Promotes Apoptosis In Vitro, and Inhibits Orthotopic Prostate Tumor Growth and Metastasis in Mice.

12. Klatte T, Chung J, Leppert JT, Lam J, Pantuck AJ, Figlin RA and Belldegrun AS: Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma.
13. Lam JS, Patard J, Goel R, Guille F, Lobel B, Abbou C, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips T, Zigeuner R, Pantuck AJ, Figlin RA, and Belldegrun AS: SIGNICANCE OF TUMOR SIZE IN LOCALLY ADVANCED RENAL CELL CARCINOMA (pT3a): AN INTERNATIONAL MULTICENTER EXPERIENCE
14. Karakiewicz KI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, and Patard JJ: PLATELET COUNT AND PREOPERATIVE HAEMOGLOBIN DO NOT SIGNIFICANTLY INCREASE THE PERFORMANCE OF ESTABLISHED MODELS FOR PREDICTING RENAL CELL CARCINOMA SPECIFIC SURVIVAL.
15. Pantuck AJ, Seligson D, Klatte T, Wu H, Leppert J, Lam J, O'Toole T, Dukart G, Gibbons J, Belldegrun AS, Figlin RA: Prognostic relevance of the mTOR pathway in renal cell carcinoma - implications for molecular patient selection for targeted therapy.

#### CHAPTERS:

1. Pantuck AJ, Cummings KB: Surgery for renal cell carcinoma involving the inferior vena cava. Atlas of the Urologic Clinics of North America, 6(1):51-72, 1998.
2. Pantuck AJ, Zisman A, Belldegrun A: Biologic therapy for prostate cancer: new approaches and preliminary results. Prostate Cancer, Schattauer, 2001.
3. Pantuck AJ, Zisman A, Belldegrun A: Kidney cancer. Urology Highlights 2000-2001, Health Press.
4. Pantuck AJ, Zisman A, Belldegrun AS: Immunologic therapy for renal cell carcinoma. In: Belldegrun, Ritchie, Figlin, Oliver, Vaughan, eds: Renal and Adrenal Tumors, Oxford University Press, pp. 343-350, 2003.
5. Pantuck AJ, Zisman A, Belldegrun AS: Basic biology and clinical behavior of renal cell carcinoma. In: Belldegrun, Ritchie, Figlin, Oliver, Vaughan, eds: Renal and Adrenal Tumors, Oxford University Press, pp. 81-89, 2003.
6. Zisman A, Pantuck AJ, Belldegrun AS: Lymphadenectomy for renal cell carcinoma. In: Belldegrun, Ritchie, Figlin, Oliver, Vaughan, eds: Renal and Adrenal Tumors, Oxford University Press, pp. 318-323, 2003.

7. Pantuck AJ, Rauch M, Zisman A, Belldegrun AS: Diagnosis and management of the incidental renal mass. In: Belldegrun, Ritchie, Figlin, Oliver, Vaughan, eds: Renal and Adrenal Tumors, Oxford University Press, pp. 31-39, 2003.
8. Han K, Pantuck AJ, Belldegrun AS: Basic biology and staging for renal cell carcinoma. In: Figlin RA, ed: Kidney Cancer. Kluwer Academic Publishers, pp. 69-89, 2003.
9. Pantuck AJ, Zisman A, Belldegrun AS: Cryosurgical ablation of the prostate for localized prostate cancer: background, technique, and results. In: Cummings, KB, ed: Management of Prostate Cancer: Advances and Controversies. Marcel Dekker, New York, NY.
10. Pantuck AJ, Lieberman R, Shvarts O, Kawaoka K, Lamm, D: Nutritional chemopreventive approaches to bladder cancer. In Heber D, ed: Nutritional Oncology, Academic Press, NY.

#### **CHAPTERS IN PRESS:**

1. Leppert JT and Pantuck AJ: Pomegranate Juice and Prostate Cancer Chemoprevention.

#### **NON-PEER-REVIEWED PAPERS:**

1. Zisman A, Pantuck AJ, Belldegrun AS: Immune and genetic therapies for advanced renal cell carcinoma. Reviews in Urology, 2:54-60, 2000.
2. Pantuck AJ, Zisman A, Belldegrun AS: Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. Reviews in Urology, 2:22-24, 2000.
3. Pantuck AJ, Zisman A, Belldegrun AS: Innovative strategies proposed at the Western AUA meeting. Highlights from the annual meeting of the Western Section of the American Urological Association. Reviews in Urology, 2:4-10, 2000.
4. Pantuck AJ, Zisman A, Belldegrun A: Molecular markers for RCC. Reviews in Urology, 2:171-172,2000.

5. Pantuck AJ, Zisman A, Belldegrun A: 95<sup>th</sup> American Urological Association Annual Meeting: Best of the 2000 AUA Annual Meeting. Reviews in Urology, 2:135-137, 2000.
6. Pantuck AJ, Zisman A, Belldegrun AS: What's hot in the prostate? Highlights from the annual meeting of the Western Section American Urological Association. Prostate Cancer and Prostatic Diseases 2:215-217, 2000.
7. Freedland S, Pantuck AJ, Zisman A, Belldegrun A: Tumor cell vaccines for renal cell carcinoma. Reviews in Urology, 3:21, 2001.
8. Freedland S, Chao D, Pantuck AJ, Zisman A, Belldegrun AS: New diagnostic and therapeutic modalities for TCC, RCC and Testicular cancer. Reviews in Urology, 3:33-35, 2001.
9. Zisman A, Pantuck AJ, Belldegrun AS: Molecular based therapies for renal cell carcinoma. Current Urology Reports, 2:55-61, 2001.
10. Gitlitz B, Pantuck AJ, Figlin R, Belldegrun AS: Dendritic cell-based immunotherapy for advanced renal cell carcinoma. Current Urology Reports, 2:46-52, 2001.
11. Chao D, Freedland S, Pantuck AJ, Zisman A, Belldegrun A: Bladder Cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Reviews in Urology, 3:85-93, 2001.
12. Pantuck AJ, Belldegrun AS: Phase I clinical trial of Interleukin-2 gene therapy for prostate cancer. Current Urology Reports, 2:33, 2001.
13. Zisman A, Pantuck AJ, Freedland S, Belldegrun A: Urology in the desert 2000: highlights from the 76<sup>th</sup> annual meeting of the Western Section American Urological Association. Reviews in Urology, 3:99-101,2001.
14. Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS: Immunotherapy of prostate cancer. Current Urology Reports, 2:242-247, 2001.
15. Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, and Belldegrun AS: Minimally Invasive Ablative Approaches in the Treatment of Renal Cell Carcinoma. Current Urology Reports, 3:13-20, 2002.

16. Freedland S, Bui M, Chao D, Pantuck AJ, Zisman A, Belldegrun AS: Biomarkers for early detection and optimized treatment for transitional cell carcinoma. Reviews in Urology, 3:210-212, 2002.
17. Han K, Pantuck AJ, Zisman A, Bui M, Belldegrun AS: Best of the AUA Annual Meeting. Reviews in Urology, 3:193-206.
18. Perry K, Zisman A, Pantuck AJ, Janzen N, Schulam P, Belldegrun AS: Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Reviews in Urology 4:103-111, 2002.
19. Kim H, Pantuck AJ, Zomorodian N, Belldegrun AS: Monoclonal antibody in patients with advanced cancer: phase I clinical results. Current Urology Reports, 4:11-12, 2003.
20. Pantuck AJ, Zisman A, Belldegrun AS: Urologic oncology: extraordinary opportunities for discovery. Highlights from the 2<sup>nd</sup> annual winter meeting of the Society of Urologic Oncology. Reviews in Urology, 5:26-28, 2003.
21. Pantuck AJ: Prognostication and clinical outcome algorithms for renal cell carcinoma. In: A. Pantuck, Ed.: Advances in the Management of Renal Cell Carcinoma. Proceedings of the Irish Society of Surgical Oncology. Excerpta Medical International. The Netherlands, 2003.
22. Pantuck AJ: The role of nephrectomy and immunotherapy in a combined approach to metastatic kidney cancer. In: A. Pantuck, Ed.: Advances in the Management of Renal Cell Carcinoma. Proceedings of the Irish Society of Surgical Oncology. Excerpta Medical International. The Netherlands, 2003.
23. Shvarts O and Pantuck AJ: The Use of [<sup>11</sup>C]choline in Localizing Recurrent Prostate Cancer. AUA News, 2004.
24. Pantuck AJ, Figlin RA: Cytoreductive nephrectomy and interleukin-2 for metastatic renal cell carcinoma. Biotherapy 7(1):1-4, 2004.
25. Shvarts O, Lam J, Figlin R, Belldegrun A, and Pantuck AJ: Improving postnephrectomy follow-up in RCC patients. Contemporary Urology, 16:18-27, 2004.

**NON-PEER-REVIEWED PAPERS IN PRESS:**

1. Han K, Pantuck AJ, Belldegrun AS: A randomized Phase III trial of high dose Interleukin-2 versus subcutaneous Interleukin-2/Interferon. Current Urology Reports.
2. Pantuck AJ, Zisman A, Belldegrun A: Cytoreductive nephrectomy plus immunotherapy improves survival for patients with metastatic kidney cancer. Reviews in Urology.

**PUBLISHED ABSTRACTS:**

1. Benson MC, Whang IS, Pantuck AJ, Ring K, Kaplan S, Olsson CA, Cooner W: Prostate Specific Antigen Density: A Means of Distinguishing BPH and Prostate Cancer. Journal of Urology, 145(4):382A, 1991.
2. Kraus SR, Villanueva J, Weiss RE, Pantuck AJ, Gwodz P, Sleat D, Lobel P, Raska K, Cummings KB: Mannose 6 phosphorylated glycoproteins in prostate adenocarcinoma: A predictor of PSA elevation after radical prostatectomy. Journal of Urology, 157(4):442A, 1997.
3. Cummings KB, Sarvazyan AP, Pantuck AJ, Ward SW, Weiss RE: Mechanical Imaging: A novel device for prostate imaging. Journal of Urology, 157(4):122A, 1997.
4. Weiss RE, Sarvazyan AP, Fishman V, Pantuck AJ, Ward SW, Cummings KB: Development of a database for three dimensional imaging of prostate disease. Journal of Urology, 157(4):420A, 1997.
5. Villanueva J, Kraus S, Pantuck AJ, Weiss R, Sleat D, Cummings K, Lobel P, Raska K: Mannose 6-phosphate glycoproteins in prostate carcinoma: A new marker for post operative rise in serum PSA? American Journal of Clinical Pathology, 107(4):468A, 1997.
6. Pantuck AJ, Murphy DP, Amenta PS, Das KM, Cummings KB, Weiss RE: The monoclonal antibody 7E12H12 can differentiate primary adenocarcinoma of the bladder and prostate. Journal of Urology, 159 (5): 928A, 1998.
7. Pantuck AJ, Bancila E, Das K, Amenta PS, Cummings KB, Marks M, Weiss RE: Adenocarcinoma of the urachus and urinary bladder express a unique colonic epithelial epitope: An immunohistochemical study. Yearbook of Clinical Pathology, 1998.

8. Zisman A, Patel BJ, Pantuck AJ, Tso CL, Belldegrun AS: An androgen independent, fluorescence tagged metastatic tumor model for hormone refractory metastatic prostate cancer. Proc AACR 2000.
9. Zisman A, Pantuck AJ, deKernion JB, Tso CL, Belldegrun AS: G250-GMCSF: a novel RCC specific tumor vaccine. Journal of Urology 163:108A, 2000.
10. Pantuck AJ, van Ophoven A, Gitlitz B, Tso CL, Stiles A, Acres B, Ross M, Figlin R, Belldegrun A: MUC-1/IL-2 gene therapy for advanced prostate cancer: phase I trial and clinical response associated systemic immune activation. Journal of Urology 163:158A, 2000.
11. Zisman A, Pantuck AJ, Patel BJ, Tso CL, Belldegrun A: CL1-GFP: a novel hormone refractory and metastatic prostate cancer model tagged with green fluorescence. Journal of Urology 163:102A, 2000.
12. Pantuck AJ, Zisman A, Shvarts O, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Natural history and the role of nephrectomy in the biology of RCC: the UCLA experience. Proc ASCO 19:343a, 2000.
13. Pantuck AJ, Zisman A, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Regional lymphadenopathy during cytoreductive nephrectomy predicts IL-2 failure in patients with metastatic renal cell carcinoma. Proc ASCO 20(1):172a, 2001.
14. Zisman A, Pantuck AJ, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: UISS: A novel integrated staging system better predicts survival of patients with renal cell carcinoma. Proc ASCO 20(1):181a, 2001.
15. Belldegrun A, Zisman A, Pantuck AJ, Gitlitz BJ, Figlin RA: Aggressive surgical resection and immunotherapy improves survival of patients with metastatic renal cell carcinoma: the UCLA experience. Proc Asco 20(2):177b, 2001.
16. Pantuck A, Matherly J, Zisman A, Wu L, Belldegrun A: Second generation suicide gene therapy using herpes simplex virus thymidine kinase mutants for advanced prostate cancer. J Urol 165:291A, 2001.
17. Belldegrun A, Zisman A, Pantuck AJ, Dorey F, Gitlitz B, deKernion JB, Figlin R: Cytoreductive nephrectomy and adjuvant immunotherapy significantly prolong life of patients with metastatic renal cell carcinoma. J Urol 165:184A, 2001.
18. Zisman A, Pantuck AJ, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Should tumor size cut off point between RCC stages T1-1997 and T2-1997 be lowered? J Urol 165:158A, 2001.

19. Zisman A, Pantuck AJ, Chao D, Dorey F, Gitlitz B, deKernion JB, Figlin R, Belldegrun A: Improved prognostication using a novel integrated staging system for renal cell carcinoma. *J Urol* 165:161A, 2001.
20. Belldegrun A, Pantuck AJ, Lohner M, Xiao-dong Y, Roskos L, Schwab G, Weiner L, Figlin R: A fully human anti-epidermal growth factor receptor (EGFr) antibody in patients with renal or prostate cancer. *J Urol* 165:182-183A, 2001.
21. Cummings KB, Pantuck AJ, Glazier DB: Nerve-sparing radical retropubic prostatectomy: refining the anatomic approach. *J Urol* 165:181A, 2001.
22. Pantuck AJ, Freeland SJ, Zisman A, Matherly J, Tso CL, Belldegrun AS: A fluorescence labeled, single-cell derived, metastatic tumor model for hormone refractory prostate cancer. Proc AACR 42:913-914, 2001.
23. Freeland SJ, Pantuck AJ, Tso CL, Zisman A, Matherly J, Belldegrun AS: Cellular and molecular characterization of the heterogeneity of hormone refractory prostate cancer using a unique single cell derived and GFP expressing clonal tumor model. Proc AACR, 42:513, 2001.
24. Zisman A, NG CP, Pantuck AJ, Tso CL, Bonavida B, Belldegrun AS: Actinomycin D and gencitabine synergistically sensitize androgen-independent prostate cancer cells to APO2/TRAIL mediated apoptosis. Proc AACR 42:438-439, 2001.
25. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Gambhir S, Wu Lily, Belldegrun AS: CL1-SR39: a non-invasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. The Journal of Urology, 167:388, 2002.
26. Pantuck AJ, Lu Q, Zhang ZF, Belldegrun AS, Rao J: Chemoprevention of bladder cancer using green tea polyphenol extract: the effect of green tea on cell proliferation and F/G actin ratio. The Journal of Urology, 167:122, 2002.

27. Pantuck AJ, Zisman A, Chao D, Dorey F, Flanigan R, deKernion J, Figlin R, Belldegrun AS: Survival advantage of Interleukin-2 over Interferon immunotherapy when combined with cytoreductive nephrectomy based on SWOG 8949-matched populations. The Journal of Urology, 167:166, 2002.
28. Zisman A, Pantuck AJ, Chao D, Dorey F, Said J, deKernion J, Figlin R, Belldegrun AS: Renal cell carcinoma with IVC extension: the role of nephrectomy, immunotherapy and the relevance of the 1997 TNM staging system. The Journal of Urology, 167:169, 2002.
29. Zisman A, Pantuck AJ, Chao D, Dorey F, Said J, deKernion J, Figlin R, Belldegrun AS: UISS-based clinical algorithm to predict outcome of patients with localized and advanced renal cell carcinoma. The Journal of Urology, 167:169, 2002.
30. Freedland SJ, Liu A, Pantuck AJ, Zisman A, Nguyen D, Tso CL, Paik S, Belldegrun AS: In vivo modeling of prostate cancer progression using a novel fluorescent-labeled, clonal tumor system. The Journal of Urology, 167:143, 2002.
31. Hernandez J, Bui M, Han K, Pantuck AJ, Zisman A, Freitas D, Tso CL, Paik S, Belldegrun AS: Generation of a vaccine for renal cell carcinoma based on the fusion protein G250-GMCSF. The Journal of Urology, 167:125, 2002.
32. Hernandez J, Bui M, Han K, Pantuck AJ, Zisman A, Freitas D, Tso CL, Paik S, Belldegrun AS: Generation of a vaccine for renal cell carcinoma based on the fusion protein GMCSF-G250. Proc AACR, 43:659, 2002.
33. Lu Qingyi, Pantuck AJ, Jin J, Zhang Z, Belldegrun AS, Rao JY: Chemoprevention of bladder cancer using green tea polyphenol extracts—the effect of green tea on cell proliferation and F/G actin ratio. Proc AACR, 43:643, 2002.
34. Rao JY, Seligson D, Visapaa H, Horvath S, Michel K, Pantuck AJ, Belldegrun AS, Palotie A: Tissue microarray analysis of cytoskeletal actin associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Proc AACR, 43:899-900, 2002.
35. Pantuck AJ, Zisman A, Chao D, Dorey F, deKernion JB, Figlin RA, Belldegrun AS: A comparison of Interferon versus Interleukin-2 following nephrectomy for metastatic renal cell carcinoma. Proc ASCO, 21: 189a, 2002.

36. Han KR, Zisman A, Pantuck AJ, Freitas D, Bui M, Wieder J, Dorey F, Chao D, Gitlitz B, Figlin RA, Belldegrun AS: Renal cell carcinoma and prognostic significance of metastatic sites. Proc ASCO, 21:190a, 2002.
37. Zisman A, Pantuck AJ, Dorey F, Chao D, Said J, deKernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. Proc ASCO, 21:185a, 2002.
38. Rao J, Lu QY, Pantuck AJ, Jin Y, Zhang Z, Belldegrun A, Heber D: Green tea and its catechins stimulate actin polymerization and inhibit cell growth and motility on an in vivo bladder cancer carcinogenesis model. PROC AACR 44:1100a, 2003.
39. Han KR, Bui MHT, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukoyama H, Figlin RA, and Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. The Journal of Urology 169:172-173a, 2003.
40. Bui M, Seligson D, Han K, Pantuck AJ, Dorey F, Huang Y, Horvath S, Leibovich B, Chopra S, Liao S, Standbridge E, Lerman M, Palotie A, Figlin R, Belldegrun A: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma. Journal of Urology 169:172a, 2003.
41. Han K, Pantuck A, Freitas D, Cuevas C, Kim H, Lugg J, Childs S, Cohen J, Miller R, Shuman B, Jason M, Shore N, Moore Y, Zisman A, Krupski T, Lee J, Zincke H, Belldegrun A: Salvage Cryosurgery Using 3<sup>rd</sup> Generation Cryo "Needles" Journal of Urology 169:398a, 2003.
42. Han K, Bluemer I, Pantuck A, Zisman A, Janzen N, Kim H, Mulder P, Dorey F, Dinney C, Wood C, Swanson D, Figlin R, Belldegrun A: International Prognostication of Renal Cell Carcinoma: Journal of Urology 169:232a, 2003.
43. Palapattu GS, Pantuck A, Dorey F, Belldegrun A: Collecting System Invasion is a Poor Prognostic Factor in Renal Cell Carcinoma (RCC): Impact on Prognosis and Future Staging Classification. Journal of Urology 169:263a, 2003.
44. Zisman A, Pantuck A, Bui M, Said J, Caliliw R, Rao N, Shintaku P, Berger F, Gambhir S, and Belldegrun A: A Metastatic Tumor model for non-hereditary type 2 chromophil (Papillary) renal cell carcinoma expressing CA IX. Journal of Urology 169:142a, 2003.
45. Pantuck AJ, Seligson D, Huang Y, Horvath S, Bui M, Zisman A, Han K, Janzen N, Figlin R, Belldegrun A: KSA (EPCAM) EXPRESSION IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN RENAL

CELL CARCINOMA. Journal of Urology 169:231-232a, 2003.

46. Singer J, Pantuck AJ, Zisman A, Figlin R, Belldegrun A, Gritsch HA: Long-term outcomes of renal cell carcinoma after kidney transplantation: the UCLA experience. Journal of Urology 169:344a, 2003.
47. Leibovich BC, Pantuck AJ, Dorey F, Han K, Figlin R, Belldegrun A: Scoring algorithm to predict survival after nephrectomy and immunotherapy (SANI Score) for metastatic RCC: a stratification tool for perspective clinical trials. Journal of Urology 169:264a, 2003.
48. Moukoyama H, Han K, Pantuck AJ, Belldegrun AS: Novel kidney cancer vaccine using dendritic cells transduced with recombinant adenovirus expressing carbonic anhydrase IX for the generation of a specific cytotoxic anti-tumor response. The Journal of Urology 169:143a, 2003.
49. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ: P53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized Renal Cell Carcinoma: Implications for surveillance and adjuvant clinical trials. American Society for Clinical Oncology. New Orleans, LA, 2004.
50. Shvarts O, Said J, Lam J, Pantuck AJ, Seligson D, Aldridge M, Bui M, Liu X, Horvath S, Belldegrun A: Clinical, Pathological, and Molecular Correlations of Necrosis in the Primary Tumor of Patients with Renal Cell Carcinoma. American Society for Clinical Oncology. New Orleans, LA, 2004.
51. Glode M, Pantuck AJ, Higano C, Meyer J, Hani J, Craig S, Berenson R, Frohlich M: A phase I/II Study of Xcellerated T cells in men with hormone refractory prostate cancer. American Society for Clinical Oncology. New Orleans, LA, 2004.
52. Patard JJ, Kim H, Dorey F, Pantuck AJ, Ficarra V, Cindolo L, Zisman A, De La Taille A, Tostain J, Artibani W, Wood C, Abbou C, Lobel B, Mulders P, Chopin D, Guillé F, Swanson D, Figlin R, and Belldegrun A: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. Journal of Urology 171:437, 2004.

53. Lam J, Shvarts O, Rao P, Liu X, Li G, Figlin R, Belldegrun A, Pantuck AJ: PROGNOSTIC IMPACT OF CYTOGENETIC FINDINGS IN RENAL CELL CARCINOMA FOLLOWING SURGICAL RESECTION. Journal of Urology 171:463, 2004.
54. Patard JJ, Kim H, Dorey F, Ficarra V, Cindolo L, Zisman A, De La Taille A, Tostain J, Artibani W, Wood C, Abbou C, Lobel B, Mulders P, Chopin D, Guillé F, Swanson D, Figlin R, and Belldegrun A, Pantuck AJ: The prognostic value of histologic subtypes in Renal Cell Carcinoma (RCC). A multicenter experience in 4063 patients. Journal of Urology 171:464-465, 2004.
55. Patard JJ, Kim H, Dorey F, Pantuck AJ, Ficarra V, Cindolo L, Zisman A, De La Taille A, Tostain J, Artibani W, Wood C, Abbou C, Lobel B, Mulders P, Chopin D, Guillé F, Swanson D, Figlin R, and Belldegrun A: The use of UISS (UCLA Integrated Staging System) to predict survival in renal cell carcinoma: An international multicenter study in 4202 patients. Journal of Urology 171:437, 2004. Journal of Urology 171:437, 2004.
56. Lam J, Shvarts O, Alemozaffarder M, Kim H, Wang H, Pantuck AJ, Smith R, Belldegrun A: Nephron sparing surgery as the new gold standard for T1 < 7 cm. renal cell carcinoma: results of a contemporary UCLA series. Journal of Urology 171:469, 2004.
57. Pantuck AJ, Figlin RA, Horvath S, Fang Z, Seligson D, Belldegrun A: Characterization of Complete Responders to IL-2 Using Gene Expression Analysis and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 27:S16,2004.
58. Pantuck AJ, Baniel J, Kirkali Z, Zomorodian N, Yoosepowich O, Belldegrun AS: A novel resectoscope for transurethral resection of bladder tumors and the prostate. Journal of Endourology, 20:A317, 2006.

**PUBLISHED LETTERS, EDITORIALS, BOOK REVIEWS:**

1. Pantuck AJ: Authors' reply. Journal of Urology, 159:993-994, 1998.
2. Pantuck AJ: RE: Leech Therapy for Massive Scrotal Hematoma Following Percutaneous Transluminal angioplasty. Journal of Urology, 159:1647, 1998.

3. Pantuck AJ, Belldegrun AS: Review: Andrew Novick and Ronald Bukowski's Renal Cell Carcinoma. Molecular Biology, Immunology, and Clinical Management. Journal of Urology, 165:1058-1059, 2001.
4. Pantuck AJ, Zisman A, Belldegrun AS: Robson and the radical nephrectomy: an appreciation and historical perspective. Journal of Urology, 167(2):876-877, 2002.